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Abstract

DUAL PI3K/MTOR INHIBITION WITH BEZ235 AUGMENTS THE THERAPEUTIC
EFFICACY OF DOXORUBICIN IN CANCER WITHOUT INFLUENCING CARDIAC
FUNCTION
By David Ellis Durrant, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2015
Major Director: Rakesh C Kukreja, Ph.D.
Professor
VCU School of Medicine
Division of Cardiology

Cancer continues to be a leading cause death in the United States despite improved
treatments. Cancerous lesions form after acquiring oncogenic driver mutations or losing
tumor suppressor function in normal cells. Traditional therapies have included use of
genotoxic substances that take advantage of the increased growth rate and loss of tumor
suppressor function to cause cell death. One such drug is the anthracycline antibiotic
doxorubicin (DOX). DOX interchelates into DNA and disrupts transcriptional machinery
while also poisoning topoisomerase II. This results in single and double stranded DNA
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xv
breaks, which if severe enough leads to either necrotic or apoptotic cell death. DOX has
been very effective at treating several different cancers and is still widely used today
however its clinical use is limited due to cumulative dose dependent cardiotoxicity.
Therefore, combination therapy targeting survival pathways is utilized to minimize the
cumulative dose of DOX without ameliorating its anti-tumor effects.
We investigated the potential anti-cancer effects of combining the dual
PI3K/mTOR inhibitor, BEZ235 (BEZ), with DOX in pancreatic, breast and other cancer
cells lines as well as its associated effects on the heart. Our results showed that cotreatment of BEZ with DOX increased apoptosis in a manner that was dependent on
inhibition of the AKT survival pathway. Moreover, BEZ co-treatment with DOX had
additive effects towards cell viability while it significantly enhanced necrotic cell death
compared to either drug alone. Furthermore, we observed that physiological concentrations
of BEZ inhibited ABCB1 efflux resulting in increased intracellular accumulation of DOX,
which led to increased DNA damage. In addition, BEZ in combination with gemcitabine
(Gem) reduced cell proliferation but did not enhance necrosis or apoptosis. Treatment with
BEZ and DOX in mice bearing tumor xenographs reduced tumor growth as compared to
BEZ, DOX or Gem. Moreover, BEZ reduced DOX toxicity in rat myoblast cells and did
not potentiate the effects of DOX in tumor-bearing mice. We propose that combining BEZ
with DOX could be a novel therapeutic approach for the treatment of patients with cancer
in the hope of improving the prognosis of this deadly disease.

CHAPTER 1: Introduction

The National Cancer Institute defines cancer as when “abnormal cells divide
without control and can invade nearby tissues”. The change from normal to abnormal cells
involves a complicated and heterogeneous set of events that includes mutations within the
cancer genome and altered metabolism to give it a survival advantage over the surrounding
normal cells (1). The issue of the direct cause of initiation of cancer remains controversial
however. Mutations often occur within genes known to be tumor suppressors or oncogenes
resulting in increased activation of pathways that control cell growth, proliferation, and
survival. This change in growth rate enhances the requirement for metabolic intermediates
which is achieved by a switch to aerobic glycolysis, also known as the “Warburg Effect”
(2, 3). One theory is that genetic mutations lead to an increased proliferation and growth
rate requiring the need for an altered metabolic state. On the other hand, there is increasing
evidence that alterations to mitochondria first cause a change in metabolism which then
results in genetic alterations to increase the efficiency of their metabolic requirements (2).
Whichever the case, it is clear that both events are important to the survival and growth
advantage of cancer cells and are therefore important targets for cancer treatment.
Cancer is the second leading cause of death in the United States behind heart
disease but is expected to become the leading cause in the near future. The lifetime risk of
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developing cancer is 43% for males and 38% for females (4). However, individually these
risk percentages can be drastically altered dependent on several risk factors including
lifestyle and genetics. In general, death rates are declining in both men and women with
men seeing a large decrease in lung cancer mortality and steady decreases in colorectum
and prostate cancer while women are seeing steady decreases in the mortality rates of
colorectum and breast cancer. Much of this improvement comes from not only superior
treatments but also improved diagnosis and preventative care.
Pancreatic cancer on the other hand, has a death rate that has remained unchanged
for approximately forty years. It represents the fourth leading cause of cancer death in the
United States and the lowest five year survival rate of all the major cancers (4-6). The
reason is that symptoms are generally mild and often mistaken for other less severe
maladies, thus allowing for continued growth and infiltration of the surrounding tissue
leading to a more advanced stage at the time of diagnosis. Also, while surgery gives the
best chance for a cure, only 15% of patients are eligible because of this late stage at
diagnosis. These facts highlight the need for earlier detection and therefore an earlier stage
at diagnosis, as well as considerably better therapies.
HISTORICAL PERSPECTIVES
A brief history in cancer
Early evidence from animal specimens seems to indicate that cancer had been
around long before modern man appeared on the earth (7). The earliest known reference to
cancer comes from the Edwin Smith Papyrus which is believed to date back to 3000 BC
and describes a tumor like swelling of the breast which had was no cure (7, 8). It’s unclear
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how prevalent cancer was in ancient times but there is evidence of trying to cure patients.
Several cultures throughout the known world, including the Egyptians, Sumerians,
Chinese, and Persians, all had their cultural “remedies” that used both herbal and toxic
substances (7). The earliest accepted example of a neoplasm is from a skeleton dating to
the Neolithic period (4000 BC) which resembles signs of multiple myeloma (8).
The term cancer was derived from the words carcinos and carcinoma, which were
used by Hippocrates in ancient Greece because they reminded him of a moving crab. The
humoral theory of disease, also formulated by Hippocrates, was based on the concept that
there were four humors (blood, yellow bile, black bile, phlegm) which if kept in balance
would result in good health. From this concept of health, the earliest known theory on
cancer was formulated which suggested that cancer arose from an excess of black bile (9).
Surprisingly, this theory lasted several hundred years until dissections revealed that black
bile did not exist leading others to postulate theories, including that it is derived from
coagulated lymph, and eventually leading to the modern theory that cancer is derived from
cells, brought forth by Rudolf Virchow in 1863 with the help of microscopy (10). A Greek
physician named Aulus Celsus, who lived when Greece was part of the Roman Empire,
had great influence to modern times by making Latin the standard language of Medicine
(7). He also wrote the text De Medicina, which described several varieties of cancer and
even described breast cancer metastases to lymph nodes in the armpit. The genetic view of
cancer was formulated by a German Biologist named Theodor Boveri. Great intuition, as
well as his experience with doubly fertilized sea urchin eggs, which had chromosomes
with four poles, led him to theorize that malignant cells also have alterations to their
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chromosomes and that these alterations were the driving force behind their unlimited
growth (11). Boveri also described the linear aspect of cellular information, which we now
know are genes, and how if certain pieces of the chromosome are lost the cell can multiply
without limitation, which is the basis for tumor suppressors and oncogenes.
Cancer treatment
Early treatments for cancer included cautery, knife, salts of lead, and salts of lead
and sulfur or arsenic “Egyptian ointment”, the latter of which was in use until the 19th
century (12). Hippocrates thought that those tumors that could not be killed by fire
(cautery) were incurable and that deep seated tumor should not be treated because the
patient would die quickly. The Roman Pliny (23-79 AD) described in his Material Medica
remedies for advanced cancer which included a boiled mixture of ash of crab, egg white,
honey, and powdered feces of falcons as being his most praised remedy (7). These early
descriptions of the use of chemicals to treat cancer by the Egyptians and Greeks were fairly
sporadic until the 16th century when Paracelsus initiated a systematic use of chemicals
(13). He would travel around Europe promoting his chemical remedies and give ailing
patients samples. He introduced several toxic substances as internal remedies, including
Mercury, Lead, Sulfur, Arsenic, Iron, and Iodine but gave warning that their toxicity was
dependent on the concentration. The beginning of chemotherapy use as we know it was not
established until early in the twentieth century when nitrogen mustard, derived from World
War 2 chemical weapons testing of mustard gas, was first used to treat a patient with nonHodgkin’s lymphoma in 1943 (14). This was soon followed by the discovery of the antifolate, methotrexate, in 1948 and the first “targeted” therapy, 5-flurouracil (5-FU) in 1957.
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These early studies laid the groundwork for the development of other chemotherapies,
including the anthracyclines doxorubicin and daunorubicin, which were discovered in the
1960’s and remain some of the most effective anti-cancer drugs ever developed (15).
Surgery to remove cancerous tumors date back to at least 50AD, with the most
commonly describes surgeries being mastectomies (7). In 1655, mastectomies followed by
cauterization were performed, which no doubt improved safety of the surgery by
preventing the severe loss of blood (13). The use of various concoctions, often times
including poisons, date back to the earliest records of cancer. However, the use of
chemicals prior to surgery began in 1712 (13). This was more or less the precursor to
modern day neoaduvant therapy and was used to cure the disease prior to resorting to
surgery. Preceding the 18th century, many people including doctors thought of cancer as a
contagious disease. A change in thinking occurred though, when an English surgeon
named James Nooth inoculated himself with small pieces of breast tumor which ultimately
failed to grow (16). Around this same time, surgeons began to emphasize the examination
of wounds after tumors were removed to be sure that all pieces were sufficiently excised
knowing that fragments left behind would result in recurrence. However, it wasn’t until
1846 that anesthesia was introduced and used in the first surgery, which was to remove a
tumor. This was followed by a rapid increase in knowledge of surgery due to the advent of
anesthesia leading the next one hundred years being termed “the century of the surgeon”.
In 1895, Wilhelm Conrad Roentgen discovered X-rays and marked the beginning
of the field of radiology and radiation oncology. He took the first X-ray photograph of his
wife’s hand on a photographic plate that same year and subsequently won the Nobel Prize
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for his discovery. The following year, in 1896, radiotherapy was first used for the
treatment of a patient with gastric carcinoma (17, 18). However, because of the low
energies of X-rays, there was limited depth of penetration and therefore was mainly used
for superficial cancers. After the discovery of radium and polonium, the field of radiation
oncology grew rapidly. Radium was first used to treat a carcinoma in 1902 and was
quickly followed up by implantation directly into tumors after which it gained traction as a
wonder drug which found its way into several products (17).
These were the beginnings from which the knowledge of today was built. In the last
few decades, advances in science and technology have led to exponential growth in our
understanding of disease, including cancer. It’s from this past and the knowledge gained
from it that we must continue to push the field forward and implement new therapies in the
hopes that we can provide better outcomes to this and future generations.

DOXORUBICIN USE IN CANCER
The finding in 1943 that nitrogen mustard had anti-cancer effects spawned the
discovery of numerous chemotherapy drugs. Anthracycline antibiotics were first
discovered in the 1960’s by their isolation from the pigment producing bacteria
Streptomyces peucetius and named doxorubicin (DOX) and daunorubicin (15).
Remarkably, they are still in wide use and are some of the most successful anti-cancer
drugs ever produced. DOX remains a first-line chemotherapy agent for several cancers
including certain types of leukemia, lymphoma, and breast cancer. Despite its long history
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of clinical and laboratory use, its mechanism of action still remains controversial and is
likely a combination of several effects.
Doxorubicin mechanism: topoisomerase poisoning
What is believed to be the primary anti-cancer mechanism of DOX is through
poisoning of topoisomerase II (topo II) and to a lesser extent topoisomerase I. Topo II are
required in the nucleus to relieve under and over winding of the DNA strands as well as
DNA knots and tangles (15, 19, 20). This occurs through the introduction of a double
stranded break in the DNA that is protected through covalent interactions with tyrosine
residues on the enzyme so as to not induce mutations, deletions, or a DNA damage
response. The break in DNA allows for the passage of another DNA stand to relieve under
or over coiling to allow continuation of DNA synthesis. In normal situations these breaks
are extremely short-lived and reversible due to storage of energy in the covalent bonds
between the DNA ends and tyrosine allowing the enzyme to religate the strands without
the need for a high energy co-factor (20). However, DOX inhibits the religation step by
binding to and stabilizing the DNA-enzyme intermediate complex. This itself causes
serious effects but is amplified when DNA replication machinery or helicases traverse the
DOX stabilized DNA-enzyme complex converting these breaks into permanent fractures
no longer protected through tyrosine binding (19). The resulting fractures are prone to
mutations and recombination leading to large insertions or deletions, which if severe
enough leads to cell death. DOX also has similar effects towards topoisomerase I however
this effect is much weaker at inducing cell death than that of topo II poisoning (15).
Moreover, the deleterious actions of DOX as a topoisomerase poison are concentration
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dependent so one can infer that better delivery of the drug to the cancer cell will result in
enhanced effectiveness.
Doxorubicin mechanism: ROS formation
Whereas the primary anti-cancer effects of DOX are attributed to the poisoning of
topo II, its secondary effect and what is believed to be the primary deleterious effects
towards other cells, including cardiomyocytes, are the result of reactive oxygen species
(ROS) generation (15, 21, 22). DOX can incur a one-electron reduction to produce a
semiquinone that quickly regenerates its parent form (a futile cycle) by reducing oxygen to
form superoxide anions which are then converted to hydrogen peroxide either
spontaneously or by the enzymatic reaction of superoxide dismutase (15, 22). Hydrogen
peroxide subsequently reacts with heavy metals, including iron (the Fenton reaction), to
produce highly reactive hydroxyl radicals (22, 23). In addition, DOX can directly bind to
iron in the presence of oxygen to produce ROS (24).
Low levels of ROS generation in the cell can induce proliferation and survival
signaling but at higher levels can have several damaging effects. There are reports that
DOX induced free radicals can directly oxidize DNA bases in a similar manner as that of
ionizing radiation (15, 21, 25). The direct oxidation of bases increases the potency of DOX
in tumor cells, although it is also implicated in the mutagenicity of the drug to normal cells
and is thought to be involved in causing secondary malignancies (26). Also,
polyunsaturated fatty acids in the membrane bilayers of both the plasma membrane and the
mitochondrial membrane are susceptible to oxidation from hydroxyl radicals to form
lipoperoxyl radical (27, 28). These lipid radicals can then react with other lipids to produce
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another lipid radical and the unstable lipid hydroperoxide, including 4-hydroxy-2-nonenals
(4-HNE) (29). This could have severe effects on the health of the cells by reducing the
fluidity and breaking down of the membranes (30). Moreover, mitochondrial dysfunction
through the oxidation of cardiolipin may be an important initiation step of apoptosis by
mediating the release of cytochrome c (31).
The effects of DOX induced ROS formation on the cell amplifies the cytotoxic
effects of topo II poisoning in cancer cells and is the primary culprit in treatment related
cardiotoxicity. Thus novel therapies are needed that can amplify the anti-cancer effects of
DOX without also incurring increased toxicity in the heart.

DRUG RESISTANCE
ABC transporters
DOX is an extremely successful therapeutic, however many cells are inherently
resistant or develop acquired resistance to treatment resulting in cells which are
unresponsive to multiple structurally unrelated drugs, an occurrence which has been
termed multidrug resistance (MDR) (32, 33). There are several strategies cells use to evade
drug toxicity and incur resistance including increased survival signaling and drug
metabolism as well as decreased drug accessibility, but the vast majority of MDR in cancer
is related to the overexpression of a family of protein transporters called the ATP Binding
Cassette (ABC) transporters (32, 34, 35). The ABC transporter superfamily consists of 48
genes and 7 subfamilies (A-G) (36). In general, they are transmembrane proteins that use
the energy from ATP hydrolysis for the transport of a wide variety of substrates ranging
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from sizes of 330 daltons up to 4000 daltons and include cholesterol, lipids, cyclic
nucleotides, and several anti-cancer agents including vinca alkaloids, taxanes, nucleoside
analogs, and anthracyclines (33, 37). The proteins are either full or half transporters with
an orientation of an inverted V with the membrane spanning the protein. Upon substrate
binding, a conformational change occurs which requires binding of ATP and subsequent
hydrolysis in the nucleotide binding sites allowing for release of the substrate across the
membrane (38). When expressed at high levels, they actively pump cytotoxic agents out of
the cell resulting in reduced intracellular concentrations (32, 33, 37). This effectively
diminishes the damage incurred in the cell leading to a failure in cancer treatment.
The most commonly overexpressed transporters associated with cancer drug
resistance are ABCB1 (MDR1, p-gp), ABCC1 (MRP1), and ABCG2 (BCRP1) (35).
ABCB1, which has been shown to be overexpressed in up to 40-50% of examined cancer
patients (39, 40), along with ABCG2 are localized to the apical surface of epithelial cells
and are highly expressed in the blood brain barrier (BBB), placenta, liver, gut, and kidney
(36). ABCC1 is expressed in most tissues with high expression in the lung, testis, and
kidneys and is mainly localized to the basolateral surface (36). ABCB1 and ABCC1 are
full transporters with both having 2 transmembrane domains and two nucleotide binding
domains (35, 41). ABCG2 is a half transporter with one transmembrane domain and one
nucleotide binding domain. It forms homo or heterodimers to become functionally active
(41). There is also a high amount of redundancy among the gene substrates and studies
have shown that knockout of one gene will result in increased of expression in other
transporter genes to compensate for the loss (36).
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Although three ABC transporters (ABCB1, ABCC1, ABCG2) are most commonly
associated with cancer drug resistance, there are several others that are also known to
confer resistance to anti-cancer agents. These include the ABCC subfamily members
ABCC3, ABCC5, and ABCC10 (34, 42-44). Studies have shown that all three are involved
in transport of the nucleoside analog gemcitabine (Gem) (45) and ABCC3 was shown to be
upregulated in drug resistant patients as well as being a marker for poor clinical outcome
(42). Along with Gem, ABCC5 also confers resistance to the nucleoside analogs 6mercaptopurine and 6-thioguanine (34). ABCC10 transports several classes of anti-cancer
drugs including the vinca alkaloids, anthracyclines, and the physiological substrate
leukotriene (44). While less common in MDR, these transporters could still have serious
implications to a drugs anti-cancer efficacy and needs to be kept in mind when considering
drug treatment.
Targeting ABC transporters
Drug resistance was first described experimentally using a laboratory model of
leukemia in 1950 (46). Daunorubicin was found to be actively transported outward in drug
resistant cells that were cross resistant to vinca alkaloids and other anthracyclines in 1973
(46). Later it was found that this cross resistance was associated with a 170 kDa protein
named p-glycoprotein (ABCB1). Since then, there have been several drugs developed to
combat MDR specifically associated with overexpression of ABC transporters, but their
effectiveness has been largely underwhelming. First generation inhibitors included
verapamil, quinidine, and cyclosporine A and although there were cases that showed
promise in improving overall survival, especially in p-gp positive tumors (34, 46, 47),
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inhibitors have generally been unsuccessful and toxicity was common (32, 33). Second
generation inhibitors had improved specificity but were still found to be ineffective
clinically due to pharmacokinetic interactions which were sometimes unpredictable. Third
generation inhibitors have better pharmacokinetics and further improved specificity.
However, it remains to be seen whether they can be effective clinically. Some early data
has shown promise resulting in phase II/III clinical trials but others have demonstrated
similar toxicity issues as previous inhibitors and lack of overall effectiveness (48). For this
reason, there is a need for alternative strategies into finding useful inhibitors that combat
the active elimination of drugs from the cell, while at the same time minimizing toxicity.
One potential strategy is to find agents that aren’t specifically targeted towards ABC
transporters, but still demonstrate the ability to inhibit efflux of cytotoxic drugs, either
through direct inhibition or through competition with other substrates for access to the
binding site.
There have been several reports of drugs that have been designed and studied to
specifically inhibit various enzymes within the cell that have later been found to also
inhibit ABC-type transporters. Sildenafil (Viagra), a potent inhibitor of phosophodiesterase
5, was first shown to potentiate the anti-cancer effects of DOX against prostate cancer
when treated in combination (49). Later it was found that sildenafil inhibited the efflux
activity of both ABCB1 and ABCG2 leading to increased drug accumulation (50).
Similarly, several receptor tyrosine kinase inhibitors, including nilotinib, erlotinib, and
sunitinib, have been shown to reverse MDR in cells associated with overexpression of
ABC transporters (51-55). Rapamycin, a specific inhibitor of the mammalian target of
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rapamycin (mTOR), has also been shown to modulate the intracellular accumulation of
cytotoxic drugs through the inhibition of ABCB1 (56, 57). These drugs have dual roles in
cancer treatment by inhibiting a pathway that is commonly over activated in cancer, as
well as inhibiting the efflux capabilities of those cells, which are also commonly
overexpressed. The strategy of using a dual role inhibitor has several potential benefits.
These drugs would likely have fewer of the toxicities associated with pure ABC transporter
inhibitors due to the weaker binding and specificity. Also, inhibition of their primary
targets in combination with increasing accumulation of a secondary agent could provide a
synergistic enhancement of drug effectiveness.
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Figure 1. Mechanism of ABC transporter-mediated efflux of its substrate. ABC
transporters are primarily transmembrane proteins that are composed of two
transmembrane domains (TMD) and two nucleotide binding domains (NBD) for full
transporters or one TMD and one NBD for half transporters. Half transporters
subsequently require homo- or heterodimerization to become fully active transporters. The
substrate binding pocket is located in the center of the TMD’s which have the shape of an
inverted V. Upon substrate binding, ATP is hydrolyzed to ADP causing a conformational
shift and allowing for release of the substrate across the membrane.
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SURVIVAL SIGNALING PATHWAYS
Phosphoinositide-3-kinase signaling
Phosphoinositide-3-kinase (PI3K) and its downstream signaling partners are key
regulators of cell proliferation, survival, and differentiation. They are also frequently
mutated in cancer resulting in proteins that are stuck in a constitutively active state which
has been identified as a key event for the initiation and development of precancerous
lesions and tumor formation (58-60). PI3K is a heterodimer that is divided into three
classes (class IA and B, class II, and class III) with mainly only class IA being associated
with cancer (61). It plays an integral role in transmission of extracellular signals to
intracellular targets. Signaling initiates with activation of one of several receptor tyrosine
kinases, including human epidermal growth factor receptor 2 (HER2), epidermal growth
factor receptor (EGFR), and insulin receptor that reside in the plasma membrane (62).
Upon substrate binding, receptors homo- or heterodimerize leading to autophosphorylation
in trans on the activation loop or juxtamembrane region causing a conformational shift that
stabilizes the active state of the proteins (62). Phosphorylation of the tyrosine’s recruit
PI3K, which is made up of a p110 catalytic subunit and a p85 regulatory subunit, to the
receptors through binding of the p85 subunit to the phosphotyrosine motifs or through
adaptor proteins associated with the receptors (including insulin substrate receptor 1
(IRS1)) (63). Alternatively, RAS, which is also activated through association with
autophosphorylated receptor tyrosine kinases, can directly bind to the amino terminal
RAS-binding domain and allosterically activate PI3K (64). Association with activated
receptors or RAS on the membrane allows for a conformational change to occur leading to
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activation of the catalytic subunit which then can phosphorylate its primary target
phosphatidylinositol 4,5 bisphosphate (PIP2) to create phosphatidylinositol 3,4,5
triphosphate (PIP3) (61, 63). Formation of PIP3 by PI3K is antagonized by the
phosphatase and tensin homologue (PTEN) through dephosphorylation of PIP3 to re-form
PIP2 (61, 63, 65). The proteins 3-phosphoinoside-dependent kinase 1 (PDK1) and AKT
are recruited to the plasma membrane through binding of their pleckstrin homology (PH)
domains to PIP3. Binding of AKT to PIP3 causes a conformational change which exposes
two residues important for full activation of the protein, threonine 308 (T308) and serine
473 (S473) (61). PDK1, which is activated through interaction of its PH domain with PIP3,
phosphorylates T308 on the activation loop of AKT. To achieve full activation, AKT is
phosphorylated at S473 by the mechanistic target of rapamycin (mTOR) in complex with
RICTOR (mTORC2), whose activation remains poorly understood but seems to be
dependent on growth factors and PI3K signaling (61, 66-68). Activated AKT is involved in
the regulation of several targets including some of which that are responsible for
controlling cell survival including inhibition of Bad, Bax, forkhead box 3A (FOXO3A),
and glycogen synthase kinase-3β (66, 67). Moreover, AKT, along with extracellular signalrelated kinase (ERK), has intimate control over processes such as protein translation and
cellular growth through phosphorylation of the tuberous sclerosis complex 1 and 2
(TSC1/2) which acts to inhibit its GTPase activating protein (GAP) activity towards RAS
homolog enriched in brain (RHEB) (61, 67). RHEB bound to GTP can directly interact
with mTOR in complex with RAPTOR and PRAS40 (mTORC1) leading to activation of
its kinase activity and downstream phosphorylation of eukaryotic translation initiation
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factor 4E (eif4E)-binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1) (69). Activation of
mTORC1 and its downstream targets controls a vast array of important anabolic events. 5’
CAP dependent mRNA translation increases the translation capacity of the cell which
regulates lipid and nucleic acid synthesis, transition to aerobic glycolysis, and pentose
phosphate pathway proteins, all of which promote cell growth and proliferation (70).
Therefore, activation of the PI3K pathway plays an integral role in cancer initiation and
growth by increasing protein synthesis machinery allowing for sufficient supply of
metabolic intermediates and switch to aerobic glycolysis. Moreover, evidence suggests that
mTORC1 regulates autophagy through inhibition of a conserved protein complex
containing ULK1 or ULK2 (71). Autophagy is thought to induce a prosurvival response
when cells are undergoing metabolic or nutrient stress. It has also been shown to have
tumor suppressor effects and therefore could promote tumor progression (71).
PI3K and its downstream effectors are predominantly regulated by upstream
activation of one or more receptor tyrosine kinases. However, it can also be activated at
several points through crosstalk with other pathways which can have a significant impact
on its regulation. As mentioned previously, RAS directly binds to and activates PI3K
thereby providing a direct link between the two important signaling pathways (64). Also,
loss of signaling through MEK, a protein lying downstream of RAS and RAF, results in
activation of AKT through reduced phosphorylation of GAB1, a receptor tyrosine kinase
adaptor protein, by ERK (72). Similarly, AKT can phosphorylate RAF to negatively
regulate its activity through binding to 14-3-3 resulting in sequestration in the cytosol (64).
Moreover, ERK and RSK can cross activate mTORC1 through activation of RAPTOR and
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inhibition of the TSC1/2 complex, albeit at different inhibitory sites than that of AKT (64).
This is further supported by reports that RSK3/4 can mediate resistance to PI3K pathway
inhibition through re-activation of mTORC1 signaling (73). ERK and AKT can also act on
the same substrates to regulate cell survival. ERK and AKT both phosphorylate FOXO3A
at several sites resulting in protein degradation and cytosolic sequestration, respectively
(64, 68). In response to genotoxic insult, DNA damage response proteins are recruited to
the site of damage and activate proteins to inhibit cell cycle progression (P53) and initiate
DNA repair. DNA-PK is one of the many response proteins and is also in the same family
of kinases as PI3K and mTOR. Studies have shown that DNA-PK phosphorylates AKT at
S473 in response to genotoxic stress to induce a pro-survival response that is independent
of insulin and growth factor signaling (74, 75).
In many cancers, activation of the PI3K/mTOR pathway is key to the oncogenic
transformation of normal cells to cancerous lesions and ultimately progressing to tumor
formation. Furthermore, through inhibition of key effectors of apoptosis, like Bad, Bax,
and FOXO3A, overactivation of this pathway can lead to a drug resistant phenotype and
treatment failure. For these reasons, therapies targeting proteins along this pathway, given
as a monotherapy or in combination, could be a beneficial strategy to treat cancer by
shutting down growth and survival signaling mediated through PI3K, AKT, and mTOR.
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Figure 2. Signal transduction through PI3K. PI3K is activated through association with
substrate bound receptor tyrosine kinases and mediates the transmission of extracellular
signals to intracellular targets. Activity is negatively regulated by the phosphatase PTEN
which in normal cells helps to control activity levels of the pathway. PI3K activation
subsequently leads to activation of important downstream targets including AKT and
mTOR which, along with ERK, are integral in transmitting signals for cell growth,
survival, and proliferation.
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NVP-BEZ235
Targeted therapy as we now know it was first described in 1996 with the
development of imatinib (Gleevec), a drug that inhibits the kinase activity of the Bcr-Abl
fusion protein which is known to be expressed in up to 95% of chronic myelogenous
leukemia (76). Other targeted therapies were subsequently developed to inhibit key nodes
in the cancer cell that drives tumorigenesis. These include inhibitors of several proteins
along the PI3K/mTOR pathway, which is the most deregulated in cancer. However,
therapies directed at individual proteins, (e.g. HER2, PI3K, and mTOR) have been met
with resistance (63). Indeed, targeted inhibition of HER2 and EGFR can be overcome
through acquired mutations to proteins downstream of the receptors, including PI3K,
PTEN, and AKT, leading to reactivation of the pathway (61, 63, 67). Moreover, inhibition
of mTORC1 causes a release in feedback inhibition through IRS1 mediating reactivation
of PI3K and downstream signaling, ultimately resulting in treatment failure (61, 63, 67, 68,
77). As a result, dual kinase inhibitors which target both PI3K and mTOR have been
developed to overcome the observed resistance of targeting a single kinase. One such
inhibitor is NVP-BEZ235 (BEZ) a reversible dual PI3K/mTOR inhibitor which is active
against the four PI3K paralogs as well as the most common PI3K mutants and mTOR (78,
79). Inhibition with BEZ has effects on several downstream effectors including AKT,
ribosomal protein S6, and the translation initiation factor 4E binding protein 1. It inhibits
PI3K and both complexes containing mTOR at nM concentrations with mTOR in complex
1 being slightly more sensitive than mTORC2 or PI3K (80). BEZ has been shown to have
potent anti-proliferative qualities resulting in arrest at G0/G1 in the cell cycle that leads to
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inhibition of tumor growth (78). Moreover, previous reports utilizing several different cell
lines suggest that induction of apoptosis is dependent on the mutational status of the cancer
with HER2 amplification and PI3K mutation dependent cancers being sensitive while
those dependent on KRAS and PTEN mutations being insensitive due to resistance
mediated by activation of ERK (78, 80-85). Utilization of BEZ as a monotherapy is likely
to have a very narrow therapeutic range that is integrally dependent on the mutation status
of the cells. Furthermore, being a reversible ATP competitive inhibitor, it is likely that
removal of the drug will result in commencement of cell growth that may be more rapid
than prior to treatment. As a result, combination treatments utilizing BEZ as a sensitizing
agent towards other cytotoxic chemotherapeutics could provide much improved lasting
efficacy over individual treatments with a much wider range of tumors that could see
beneficial responses.

NEFARIOUS TOXICITIES
Doxorubicin induced cardiotoxicity
DOX has long been recognized for its beneficial effects towards tumors; however
its use has been limited by potentially severe cardiotoxicity. These effects were recognized
very early in the development of the drug with reports of cardiac dysfunction in some of
the first clinical trials, as described in a Cancer Research article from 1970 (86). The most
important risk factor in developing cardiac toxicity from DOX use is cumulative dose. A
dose greater than 400 mg/m2 results in an estimated risk of developing chronic heart failure
at 3% to 5%, however the risk increases up to 26% with doses greater than 550 mg/m2 and
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up to 48% with doses greater than 700 mg/m2 (87). In light of this, the maximum lifetime
cumulative dose is set at 550 mg/m2, which in a retrospective study found the incidence of
heart failure at this dose to be 26% (88, 89). Nevertheless, cardiac events can develop at
much lower cumulative doses if the patient presents with other risk factors like age,
diabetes, hypertension, and prior treatment with radiation therapy. DOX-induced
cardiotoxicity is grouped into three categories: acute, occurring during or immediately
following infusion; early onset, occurring within the first year after treatment; and late
onset, occurring at least one year after treatment and may not present until 10 to 20 years
after the first dose (89).
As discussed previously, what is generally believed to be the main cause of DOXinduced cardiotoxicity is through generation of ROS via one electron reduction of the
quinone moiety which then acts in a futile cycle with oxygen to produce free radicals
leading to DNA, lipid, and protein oxidative damage as well as mitochondrial dysfunction.
These cellular events induced by ROS formation contribute to cardiomyocyte cell death
from both apoptotic and necrotic pathways (87). In addition, DOX can be converted to
secondary alcohol metabolites which are less active at generating ROS but more active in
deregulating calcium and iron homeostasis (88). Correspondingly, DOX has been shown to
affect the mitochondria through increased Ca2+ levels which lead to mitochondrial swelling
due to opening of the mitochondria permeability transition pore (mPTP) thereby triggering
cell death (87).
While it is generally believed that DOX induces cardiotoxicity through increased
production of ROS, there is still debate into cause of this increase. Topo IIα, one of two
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isoforms of topo II and known to be a marker for proliferation, is overexpressed in cancer
cells but is undetectable in non-proliferating cells, including cardiomyocytes. On the other
hand, cardiomyocytes express topo IIβ but have undetectable levels of topo IIα. Studies
have shown that topo IIβ knockout cardiomyocytes are resistant to DOX-induced cell
death in part through the loss in repression of genes involved in mitochondrial biogenesis
and oxidative phosphorylation pathways (90). This change in transcriptome by DOX
affects oxidative phosphorylation and mitochondrial biogenesis pathways which is
postulated to be the reason for the observed increase in ROS production. On the other
hand, there is evidence that regulation of mitochondrial iron stores by a member of the
ABC transporter superfamily (ABCB8) plays a major role in DOX-induced ROS
production (22). Deletion of ABCB8 in mouse hearts resulted in mitochondrial iron
accumulation and development of cardiomyopathy (91). Moreover, DOX treatment
induced ROS production by increasing mitochondrial iron through decreased expression of
ABCB8 (22). Conversely, overexpression of ABCB8 reduced mitochondrial iron stores
preventing the damage incurred by DOX futile cycle-mediated ROS production. These
results are further supported by data demonstrating that the only clinically approved
cardioprotective agent for DOX-induced cardiomyopathy, dexrazoxane, works by
migrating to the mitochondria where it chelates iron. It was demonstrated that specifically
chelating iron in the mitochondria and not the cytosol was protective (22). Therefore,
evidence suggests that classical inhibition of topo II as well as iron mediated ROS
production both may be important in inducing cardiotoxicity and therefore should be
considered when designing strategies for cardioprotection.
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Combination therapy cardiotoxicity
The advent of targeted therapies brought forth the hope of preferentially killing
cancer cells without the severe side effects that plague cytotoxic agents like DOX by
shutting down signaling pathways key to cancer cell survival. Unfortunately, these have
also been met with rapid resistance leading to continued growth of the tumors and
recurrence. Moreover, the same signaling pathways that are important for cancer cell
survival also regulate important processes in cardiomyocytes which can lead to deleterious
effects on the heart (92). Indeed, clinical use of several kinase inhibitors has been reported
to induce some form of cardiac dysfunction including hypertension, declines in left
ventricular function, and congestive heart failure (87, 92, 93). Mechanistic reasons for the
effects on the heart seem to point towards disruption of neuregulin-HER2 signaling, loss of
survival signaling through ERK and PI3K, deregulation of calcium handling, and
mitochondrial swelling (92).
Still, cardiac events using monotherapy of tyrosine kinase inhibitors are relatively
rare and many times reversible. However, in the need to improve therapeutic efficacies
against tumors, therapies combining targeted agents and cytotoxic agents are becoming
tested with increasing frequency and have subsequently been found to have a high amount
of toxicity, especially cardiotoxicity (94-96). HER2, for example, is highly expressed in
certain forms of breast cancer so combining the anti-HER2 monoclonal antibody
trastuzumab with a standard chemotherapy regimen of DOX and cyclophosphamide
became an attractive strategy to gain better control over the tumor. While the combination
did have significant improvement in objective response over DOX alone (50% vs 32%), it
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also saw an increase in cardiac dysfunction which was present in 27% of the patients
compared to 8% of those who received only DOX and cyclophosphamide (97). In addition,
preclinical reports using the HER2/EGFR inhibitor lapatinib, have shown that it greatly
potentiates the myocyte damaging effects of DOX (94). Similarly, neuregulin, an activator
of erbB2 (HER2) and erbB3, has been demonstrated to protect cardiomyocytes against
DOX-induced toxicity (98). These studies highlight the critical role that HER2 and other
receptor tyrosine kinases play in the survival of cardiomyocytes when undergoing stress.
Likewise, conditional knockouts of proteins along the PI3K/mTOR pathway in the heart
develop cardiomyopathy and are more susceptible to damage from stress (95). On the other
hand, lapatinib in combination with DOX reduced ERK phosphorylation but not AKT
suggesting that ERK may be more important in protecting myocytes from DOX than AKT
(94). In light of these studies, targeted inhibition of only one of the survival pathways
(ERK or AKT) may provide a sufficient sensitizing effect to cancer cells without
completely shutting down survival signaling in cardiomyocytes providing a muted toxicity
profile compared to receptor tyrosine kinase inhibitors like trastuzumab.

CURRENT STUDY
The major goal was to investigate the effect of BEZ in enhancing the efficacy of DOX
in KRAS or p53 mutant cancers particularly the pancreatic, breast, colon, and lung. We
hypothesized that BEZ will sensitize cancer cells to DOX through inhibition of survival
signaling and increased activation of pro-apoptotic proteins. Furthermore, based on
previous clinical studies with trastuzumab and DOX showing increased risk of heart failure
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when the drugs were treated in combination (97), we tested whether inhibition of
PI3K/mTOR pathway signaling in the heart would potentiate the cardiotoxic effects of
DOX. Accordingly, the specific goals of the study were as follows:

1) Interrogate the novel interaction of BEZ with ABC transporters and how this could
affect cell sensitization to DOX.
2) Explore the mechanism by which BEZ sensitizes cancer cells to DOX through its
inhibition of PI3K and mTOR and modulation of apoptosis-related proteins.
3) Determine whether combination treatment with BEZ and DOX has superior in vivo
anti-tumor effects than individual drug treatments.
4) Examine the effects of the combination treatment with BEZ and DOX on
mechanism of cell death in cardiomyocytes and cardiac function in tumor bearing
mice.

We show that BEZ has a potent and selective sensitizing effect on DOX but not
Gem in all KRAS or P53 mutant cancers tested. Furthermore, for the first time we show
that physiological concentrations of BEZ treated in combination with DOX enhanced drug
accumulation which resulted in increased DNA damage and ROS production. Moreover,
expression of the anti-apoptotic protein Bcl-2 is reduced while the smaller, more cytotoxic
forms of BIM are enhanced to favor apoptosis. Importantly, the increase in cancer
chemotherapeutic efficacy did not result in a deterioration of DOX-induced cardiac
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dysfunction. Based on these results, we propose that combining BEZ with DOX could be a
potential therapeutic option for patients with pancreatic and other cancers. It is our hope
that such a strategy may turn out to be significantly better than currently used regimens.

CHAPTER 2: Materials and Methods

Cell lines. MiaPaCa2 pancreatic cancer cells (MIA PaCa-2 ATCC CRL-1420), MDA-MB231 (MDA-MB-231, ATCC HTB-26) and Mcf7 (MCF7 (ATCC HTB-22) breast cancer
cells were obtained from American Type Culture Collection. Upon receiving the cells, they
were thawed and expanded after which several stocks were frozen in liquid nitrogen. For
experimental use, cells were thawed from a stock frozen in liquid nitrogen starting with
passage number of 4 and discarded before passage number 20. Capan-1, and CD18 were
obtained from Dr. Surinder Batra from the University of Nebraska Medical Center. HCT
116 and H1299 cells were obtained from Dr. Steven Grossman from Virginia
Commonwealth University Medical Center. No cell line authentication was conducted by
the authors. All cells were grown in DMEM medium supplemented with 10%FBS, 100
units/ml penicillin, and 100 μg/ml streptomycin. Mia-dx drug resistant cells were derived
from MiaPaCa2 cells through step wise treatment with increasing concentrations of DOX.
In short, starting at 0.2 μM, cells were incubated with DOX for periods of 2 hours once
every two to three weeks (depending on recovery time). Concentrations were increased by
0.1 μM at every treatment, up to a final concentration of 1 μM. After this point, cells were
grown in DMEM medium supplemented with 10%FBS, 100 units/ml penicillin, 100 μg/ml
streptomycin, and 0.05 μM DOX. Mia-B1 cells were derived by transfecting MiaPaCa2
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cells with the pHAMDRwt plasmid containing the full length ABCB1 gene. After
transfection, ABCB1 overexpressed cells were selected by culturing in 0.5 μM DOX until
colonies were formed and all non-transfected control cells were dead. Colonies were
picked to obtain a single colony population. Cells were then grown in DMEM medium
supplemented with 10%FBS, 100 units/ml penicillin, 100 μg/ml streptomycin, and 0.05
μM DOX. A2780 ovarian cancer cells were grown in RPMI medium supplemented with
10%FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin. A2780-dx drug resistant
cells were derived from A2780 cells through stepwise treatment with DOX as previously
described. After selection, cells were grown in RPMI medium supplemented with
10%FBS, 100 units/ml penicillin, 100 μg/ml streptomycin, and 0.05 μM DOX.
pHAMDRwt plasmid (Addgene #10957) was obtained from Addgene and supplied by
Michael Gottesman.
Compounds and reagents. BEZ235 (#NC9953953) and gemcitabine (#NC0063515) were
purchased from Fisher Scientific and Doxorubicin (#D1515-10MG) was purchased from
Sigma-Aldrich. Sildenafil was a gift from Pfizer. Antibody for actin-HRP (#sc1616) was
purchased from Santa Cruz Biotechnology. Phospho-S6 ribosomal protein (#4858), S6
ribosomal protein (#2217), Phospho-AKT 473 (#4060), Phospho-AKT 308 (#13038), AKT
(#9272), Phospho-ATM (#5883), Phospho-chk2 (#2661), Bcl-2 (#2870), Bax (#2772) and
cleaved-PARP (#5625) were purchased from Cell Signaling Technology. Secondary
antibody was purchased from VWR (#95017-556). Trypan blue dye (#T8154) was
purchased from Sigma-Aldrich. TUNEL assay was purchased from Fisher Scientific
(#NC9027080). Carboxy-H2DCFDA was purchased from Life Technologies (C400).
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Cell viability. Cell viability was measured using the CellTiter 96 Aqueous One assay from
Promega. Cell lines were plated at a density of 5000 cells/well in a 96 well plate for 48
hours in non-treated growth medium in an incubator set at 37oC and 5% CO2. Cells were
then treated with drugs at the indicated concentrations for an additional 48 hours in the
incubator. After treatment, medium was replaced with 100 μl of Aqueous One solution
according to Promega’s protocol and incubated at 37oC for one hour. Viability was
assessed by measuring the absorbance of each well using a 96 well plate
spectrophotometer.
Trypan Blue cell death assay. Cells were plated into 6-well tissue culture plates at a
density that would result in confluence of 70-80% after incubation for 48 hours. Cells were
then treated in triplicate for the indicated time. Media was removed and placed into a
centrifuge tube. 1 ml of 1x PBS was then added to the plates to remove any residual media
after which it was placed into the corresponding centrifuge tube. Attached cells were
trypsinized, collected and then added to its corresponding tube containing the media and
PBS wash. Cells were pelleted by centrifugation and supernatant discarded. Cell pellet was
re-suspended in normal media and 100 μl of cell suspension was mixed with 100 μl of
Trypan Blue dye and placed onto a hemocytometer. Live (unstained) and dead (stained)
were quantified under a microscope.
TUNEL assay. DNA fragmentation was measured using the ApoAlert DNA
Fragmentation assay from Clontech and purchased from Fisher Scientific (#NC9027080).
Slides were prepared using the protocol from Clontech. In short, cells were plated on 4chamber microscope slides and allowed to attach for 48hours. They were then treated for
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an additional 24 hours with the indicated concentrations of drug and fixed in 4%
paraformaldehyde for 15 minutes at room temperature. After fixation, they were washed
with 1x PBS and incubated in 100% methanol for 10 minutes in -20oC. The slides were
then washed with PBS and stored at -20oC in 70% ethanol. Cells were permeablized with
0.2% Triton X-100 for 5 minutes on ice after which they were washed in PBS. Slides were
then incubated in equilibration buffer for 10 minutes after which they were incubated with
TDT incubation buffer for 60 minutes at 37oC. Reaction was then terminated in SSC,
washed, and coverslips added. TUNEL positive cells were visualized using the NIKON
Eclipse Ti confocal microscope.
Immunoblot analysis. After treatment, cells were washed twice with 1x PBS then pelleted.
Pellets were lysed with 1x lysis buffer (Cell Signaling #9803) plus 1 to 100 dilution
protease inhibitor cocktail (Thermo Scientific #78410) and incubated on ice for 30 minutes
after which samples were centrifuged at 12,000g for 10 minutes at 4oC to remove insoluble
debris (debris pellet was used for DOX accumulation measurements described below).
Supernatant was collected and protein measured using manufacturer’s protocol (Bio-Rad
Protein Assay reagent #500-0006). Samples were combined with 2x Laemmli sample
buffer (Bio-Rad #161-0737) and boiled for 5 minutes after which proteins were separated
using SDS-PAGE on 4%-20% TGX gradient gel (Bio-Rad #567-1093) and transferred to
nitrocellulose paper (Bio-Rad #162-0232). After blocking non-specific binding sites with
5% milk in 1x TBS-T (tris buffers saline with 0.05% tween), membranes were incubated
with the primary antibodies at 4oC overnight, washed 4x for 10 minutes each with TBS-T
and incubated an additional one hour with a secondary antibody. Membranes were then
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washed 4 times with TBS-T for 10 minutes each and visualized using Western Lighting
ECL plus (Perkin Elmer #NEL105001) and exposed on BioMax light film (Kodak
#1788207).
DOX accumulation studies. Cells were plated in 6 well plates at a density of 20,000
cells/well and incubated at 37oC for 48 hours. After the 48 hour incubation, DOX (0.2 μM)
was added in the presence or absence of the indicated concentrations of inhibitor. After 48
hours more, cells were trypsinized, washed twice with 1x PBS and re-suspended in 1 ml of
1x PBS. DOX was accumulation measured by flow cytometry using excitation wavelength
of 488 nm.
DOX efflux studies. Cells were plated in 6 well plates at a density of 20,000 cells/well and
incubated at 37oC for 48 hours. After the 48 hour incubation, DOX (5 μM) was added in
the presence or absence of the indicated concentrations of inhibitor. After one hour,
medium was replaced, without DOX, in the presence or absence of inhibitor for two hours.
Cells were then trypsinized, washed twice with 1x PBS and re-suspended in 1 ml of 1x
PBS. DOX accumulation was measured by flow cytometry using excitation wavelength of
488 nm.
Intracellular DOX accumulation. DOX was measured using the debris pellet from protein
lysate preparation which contains the majority of the DOX. After centrifugation, pellet was
re-suspended in 400 μl of acidified alcohol (50ml of 70% ethanol and 375 μl 12N HCl)
then incubated at -200C overnight followed by centrifugation at 20,000 g for 10 minutes.
Supernatant was aliquoted in triplicate into a black 96 well polystyrene microplates (VWR
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# 82050-728) and fluorescence measured at excitation of 485 nm and emission of 595 nm
using Molecular Devices Spectramax M5 plate reader.
Immunofluorescence staining. Cells were plated on 4-well glass chamber slides (World
Wide Medical Products #354577) at a density of 10,000 cells/well and allowed to grow for
48 hours. Cells were then fixed in 4% paraformaldehyde for 15 minutes at room
temperature and washed three times with 1x PBS for 5 minutes each. Cells were then
incubated for 1 hour in blocking buffer (5% normal goat serum, 0.3% Triton X-100 in 1x
PBS) followed by incubation with primary antibody in blocking buffer overnight at 4oC.
Thereafter, slides were washed three times in 1x PBS for 5 minutes each and then
incubated with secondary antibody in blocking buffer an additional 1 hour. The slides were
subjected to three additional washings in 1x PBS were performed after which hard set
mounting medium (Vectasheild #H1500) was added and cover slips placed. Proteins were
visualized using the NIKON Eclipse Ti confocal microscope.
ROS measurement. MiaPaca2 cells were seeded into a 96-well tissue culture plate at a
density of 15,000 cells/well in phenol-free medium. After 24 hours, carboxy-DCFDA (Life
Technologies #C-400) was added at a concentration of 20 μM in phenol-free medium and
incubated at 37oC for 30 minutes. The wells were then washed one time with 1x PBS after
which drugs (diluted in phenol-free medium) were added at a volume of 100 μl. DCFDA
fluorescence was measured at 6 hours using the setting for excitation at 485nm and
emission at 535 nm using Molecular Devices Spectramax M5 plate reader.
ATPase assay. ATPase activity was measured to test BEZ235’s capacity to be an ABCB1
substrate. Assay protocol (Promega #V3601) was followed according to manufacturers’
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guidelines. Briefly, drugs were incubated with assay buffer, p-gp membranes, and ATP for
40 minutes at 37oC. Detection reagent was added then incubated for an additional 20
minutes at room temperature after which the luminescence was measured.
Animal studies. All mice were maintained in the vivarium at Virginia Commonwealth
University and kept in accordance to a protocol approved by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University. Female 8-10 week old
Athymic NCr nu/nu mice were inoculated with of 1 x 106 MiaPaca2 cells, in a 1:1 ratio of
cells to Matrigel (BD #354234), subcutaneously into the right rear flank. Tumors were
allowed to grow for two weeks prior to initiation of treatment. DOX was dissolved in
saline and injected intravenously into the tail vein twice, two weeks apart, at a
concentration of 10 mg/kg. BEZ was dissolved in 1-Methyl-2-pyrrolidinone (NMP) and
then 0.5% sodium-carboxymethylcellulose (Na-CMC) was added so that the final volume
contained 10% NMP and 90% of 0.5% Na-CMC. BEZ was fed by oral gavage daily for 28
days at a concentration of 40 mg/kg in a volume of 0.2 ml/mouse. Gem was dissolved in
saline and injected intraperitoneally (IP) once a week for three weeks. Control, DOX, and
Gem groups were fed daily with the vehicle of the same mixture as for BEZ. Tumors were
measured twice weekly by calipers using the formula (L x W2)/2 to get the tumor volume.
Weight was measured twice weekly to monitor weight loss. Heart function was assessed
using the Vevo770 imaging system (Visualsonics, Inc.), as previously reported (99), four
weeks after start of treatment. Pentobarbital (30 mg/kg IP) was used for anesthesia.
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Statistical analysis. Statistical analysis was performed with GraphPad Prism 4.0
(Graphpad Software Inc.). Data are presented as mean ± SEM. Statistical comparisons
between 2 groups were performed with the unpaired Students t-test. One-way ANOVA
was used when comparing more than two groups followed by Newman–Keuls post hoc test
for pair-wise comparison. Two-way ANOVA was used when comparing the difference
between normal vs drug resistant cell lines. p < 0.05 was considered to be statistically
significant.

CHAPTER 3: Results

BEZ235 and doxorubicin effects on ABC transporters
Doxorubicin resistant cells overexpress ABCB1
Overexpression of ABC transporters leading to MDR is a major cause of treatment
failure in cancer patients. This increase in expression results in improved drug efflux
efficiency leading to sub-lethal intracellular levels. Therefore, it is of great interest to
discover new inhibitors of these transporters that result in reversal of the MDR phenotype
and re-sensitization of cancer cells to drug treatment. Since the early 1980’s, inhibitors that
target ABC transporters have been investigated for their ability to reverse MDR. Recently,
several inhibitors that were specifically designed to target enzymes in the signal
transduction pathway, including those targeting PI3k and mTOR, have also been found to
inhibit one or more of the ABC transporters leading to a reversal of MDR phenotypes (52,
100-102). Therefore, we set out to test the ability of the dual PI3k/mTOR inhibitor BEZ to
re-sensitize cells overexpressing ABCB1 to DOX. To investigate this, it was necessary to
create cells that overexpressed ABCB1. Two drug resistant cell lines (Mia-dx and A2780dx) were created with sequential treatment of DOX over a six month period (Figure 3A). A
third cell line (Mia-B1) was created by transfecting a plasmid carrying the MDR1 gene and
selecting with DOX to obtain drug resistant colonies (Figure 3B). Each of the drug
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resistant clones showed marked resistance to DOX in comparison to their respective
parental cell lines when assessed over a range of concentrations starting at 0.05 µM and
increasing up to 1.0 µM (Figure 4). Expression of ABCB1 was confirmed using western
blot analysis and confocal microscopy. Of the drug resistant cell lines, two (Mia-B1 and
A2780-dx) had an overexpression of ABCB1 protein, while the third (Mia-dx) had
undetectable levels of ABCB1 (Figure 5). While ABCB1 is the best studied and most
common ABC transporter related to DOX resistance, there are others that contribute to
MDR in cancer and one or more of these may be involved in the resistance of Mia-dx cells.
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A

B

Figure 3. Protocol for creating drug-resistant cell lines. (A) MiaPaca2 and A2780
parental cell lines were treated with increasing concentrations of DOX over a 6 month
period to obtain drug resistance. The starting concentration of DOX was 0.2 μM, which
was increased up to 1 μM with an incubation period of 2 hours. After treatments, cells
were washed and allowed to recover for up to 2 weeks before starting the next DOX
treatment protocol. This method created the Mia-dx and A2780-dx cell lines. (B)
MiaPaca2 parental cells were transfected with a plasmid containing the MDR1 gene. Cells
were selected using 1 μM DOX with resistant cell having overexpressed ABCB1 protein.
This method created the Mia-B1 cell line.
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Figure 4. Viability of doxorubicin (DOX)-resistant cancer cell lines.
Viability/proliferation was measured by MTS assay after challenging the cells to DOX
concentrations ranging from 0.05 to 1 μM in the pancreatic cancer cell lines (A) Mia-dx
and (B) Mia-B1, and the ovarian cancer cell line (C) A2780-dx. Cells viability was
compared to their respective parental cell lines. 2-way ANOVA was used to measure
significance. Data was plotted as mean ± SD of replicates of four. P < 0.0001 when
comparing resistant cells vs their respective parental cells for all cell lines.
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A

B

C

Figure 5. Doxorubicin (DOX)-resistance is mediated by ABCB1 overexpression.
Confocal microscope images of ABCB1 protein expression in (A) MiaPaca2, Mia-dx, and
Mia-B1 cell lines as well as (B) A2780 and A2780-dx cell lines. (C) Western blot analysis
showing expression of ABCB1 in all cell lines. Note that only Mia-B1 and A2780-dx
showed increased expression of ABCB1.
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BEZ235 treatment reverses drug-resistant phenotype
Overexpression of ABC transporters, including ABCB1, leads to increased drug
efflux efficiency which in turn decreases intracellular drug accumulation (33, 34, 103). We
wanted to test if BEZ treatment would increase accumulation of DOX in our drug resistant
cell lines. Cells seeded into 6-well plates were treated with DOX, either alone or in
combination with inhibitor for 48 hours. Taking advantage of DOX auto-fluorescence,
cells were collected and drug accumulation directly measured by flow cytometry.
Sildenafil (SIL) inhibits ABCB1 mediated drug efflux (104) and therefore was used as a
positive control. Control cells are shown as a blue peak and mark the baseline from which
to compare the shift in fluorescence intensity. Parental cells treated with DOX are shown
as a red peak which has shifted to the right indicating an increase in fluorescence intensity.
Drug-resistant cells are shown as pink peaks and inhibitor treated cells are shown as green
peaks.
SIL treatment caused a shift to the right in each drug-resistant cell line indicating
its inhibition of ABC transporters leading to an increase in DOX accumulation (Figure 4).
BEZ increased DOX accumulation to the same extent as SIL when using 50nM of drug
and completely reversed the drug resistant phenotype at 150nM in the A2780-dx cell line
(Figure 6A middle and right histogram). Similar results were seen in Mia-B1 cells,
although with a more subdued response (Figure 6B). In these cells, SIL and 50nM BEZ
showed only a minor increase in accumulation (Figure 6B left and middle histograms).
While 150nM BEZ did enhance accumulation, it was not as complete a reversal as was
observed in the A2780-dx cell line (Figure 6B right histogram). This difference is most
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likely the result of the far greater expression of ABCB1 in Mia-B1 cells. Slightly different
results were observed in the Mia-dx cell line. Mia-dx cells share the drug resistant
phenotype with Mia-B1 and A2780-dx, but lack overexpression of ABCB1. In these cells,
50nM of BEZ had little effect on increasing DOX accumulation (Figure 6C middle
histogram), and 150nM of BEZ only had minimal effects (Figure 6C right histogram). SIL
increased accumulation in these cells to a greater extent than BEZ (Figure 6C left
histogram), suggesting that BEZ may be more specific to ABCB1.
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Figure 6. Effect of BEZ235 (BEZ) on doxorubicin (DOX) accumulation in resistant
cell lines. Cells were treated for 48hr and accumulation was analyzed by flow cytometry.
The light blue peak

represents the untreated parental control, the red peak

the DOX treated parental cells, the pink peak
cell line, and the green peak

represents

represents the DOX treated drug resistant

represents the DOX treated drug resistant cell line in

combination with the indicated inhibitor. (A) A2780-dx, (B) Mia-B1, and (C) Mia-dx.
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BEZ235 directly inhibits ABCB1
Our results show that BEZ is effective at increasing the accumulation of
intracellular DOX after 48 hours of treatment. However, because BEZ inhibits key proteins
involved in the regulation of signal transduction and protein expression, it is possible that
the increased accumulation is not a result of direct inhibition of ABCB1 but because of a
reduction in ABCB1 protein expression due to reduction in translation. To test this
possibility, a drug efflux assay, which uses a much shorter treatment time of three hours,
was performed. Cells that had been grown in 6-well plates were treated for one hour with
either DOX alone or DOX in combination with the inhibitor. After one hour, the cells were
washed and the media was replaced with DOX free media with or without inhibitor for an
additional two hours to allow the cells to efflux the accumulated DOX. Cells were then
collected and DOX fluorescence was measured using flow cytometry. Similar to the results
in the 48 hour accumulation assay, BEZ and SIL were also able to inhibit DOX efflux in a
dose dependent manner in both, A2780-dx and Mia-B1, cell lines (Figure 7A and B). On
the other hand, neither SIL nor BEZ were able to inhibit efflux to a great extent in cells
which have undetectable expression levels of ABCB1, Mia-dx (Figure 7C). These results
demonstrate that BEZ is able to enhance the accumulation of DOX in ABCB1
overexpressing drug resistant cell lines through direct inhibition of the transporter.
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Figure 7. Effect of BEZ235 (BEZ) on inhibition of ABCB1 mediated doxorubucin
(DOX) efflux. Cells were treated for 1hr with DOX in combination with inhibitor (SIL or
BEZ) followed by an additional two hours incubation with inhibitor treated DOX free
media. The cells were analyzed by flow cytometry. In all histograms, the light blue peak
represents the untreated parental control, the red peak
parental cells, the pink peak
green peak

represents the DOX treated

represents the DOX treated drug resistant cell line, and the

represents the DOX treated drug resistant cell line in combination with the

indicated inhibitor. (A) A2780-dx, (B) Mia-B1, and (C) Mia-dx.
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BEZ235 is a non-substrate inhibitor of ABCB1
We have shown that BEZ can enhance accumulation of DOX in drug resistant cell
lines through direct inhibition of ABCB1. Next, we wanted to determine if BEZ inhibits
through competition of substrate (i.e. DOX) in the binding pocket or through inhibition of
the ATPase domain. When a substrate interacts with ABCB1, it stimulates the rate of ATP
hydrolysis of the transporter (38). To test the ability of BEZ to stimulate ATPase activity,
different concentrations of BEZ, along with known ABCB1 substrates (verapamil, SIL and
DOX), and an ATPase inhibitor (vanadate), were combined with isolated ABCB1 (p-gp)
membranes in the presence of ATP. ATPase activity was quantified by the amount of
inorganic phosphate released from ATP.
Each compound known to be a substrate of ABCB1 significantly stimulated ATP
hydrolysis (Figure 8A). This included DOX, although it appeared to be a fairly weak
substrate. On the other hand, in multiple experiments, BEZ either did not stimulate ATP
hydrolysis or showed only a minor stimulation as compared to the no treatment group
(Figure 8A and C).
To further examine this, parental and drug resistant cell lines were incubated with
50nM BEZ for 24 hours, and western blots were run to look at BEZ’s inhibition of
downstream mTOR signaling. If BEZ were a substrate, then inhibition of mTOR would be
diminished in ABCB1 overexpressing cell lines due to decreased accumulation. mTOR
activity in all cell lines, including those overexpressing ABCB1, was dramatically reduced
after treatment with BEZ (Figure 8B). These results suggest that accumulation of BEZ
itself was not effected and supports our previous evidence that BEZ is a poor substrate of
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ABCB1. Since BEZ inhibition of PI3k and mTOR occurs at the ATP binding site of these
kinases, it is possible that BEZ also inhibits at the ATP binding site of ABCB1, thereby
diminishing ATP hydrolysis and drug efflux efficiencies. If this were the case, BEZ should
block the stimulation of ATPase activity when a substrate is combined with the isolated pgp membranes. Our results demonstrate that vanadate is a potent inhibitor of ATP
hydrolysis, even in the presence of verapamil (Figure 8C). However, BEZ is unable to alter
the ATPase activity even at the higher concentration of 150nM indicating that it does not
inhibit at the ATP binding site of ABCB1. These results provide strong evidence that BEZ
is a poor substrate for ABCB1, and would be less likely to out-compete superior substrates
like DOX for access to the binding site. BEZ is also not an inhibitor of ATPase activity
indicating a separate inhibition profile. It is proposed BEZ is likely a non-substrate
inhibitor that can bind at the substrate binding site and act as a competitive inhibitor of
known substrates but is not a substrate itself as shown in the schematic (Figure 9).
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Figure 8. BEZ235 (BEZ) is a weak substrate for ABCB1. (A and C) An ATPase activity
assay using isolated p-gp membranes was used to determine if BEZ is a substrate of
ABCB1. Verapamil was used as a positive control for ATPase stimulation. Vanadate
inhibits ATPase activity by interacting with the ATP binding site. (B) Parental and drugresistant cell lines were treated in the presence or absence of 50 nM BEZ for 24 hours after
which cell lysates were collected to look at phosphorylation of ribosomal protein S6, a
downstream marker of mTORC1. Data is plotted as mean ± SEM of triplicates.
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B

Figure 9. Proposed mechanism for ABCB1 inhibition of BEZ235 (BEZ). (A)
Schematic showing the effect of ABCB1 on DOX accumulation. (B) Possible inhibitory
mechanism of BEZ on ABCB1 by competitive inhibition leading to increased DOX
accumulation.
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BEZ235 re-sensitizes drug resistant cells to treatment with doxorubicin
Treatment failure in cancer patients is commonly associated with the
overexpression of ABC transporters. One strategy to overcome this is to inhibit the
transporters, thereby increasing accumulation of the cytotoxic agent within the cell.
Therefore, we determined the ability of BEZ to re-sensitize ABCB1 overexpressing cells to
DOX treatment. First, cell viability was used to determine the effects of combining BEZ
with DOX after 48 hours of treatment. BEZ alone had a dramatic effect on the cell viability
of both MiaPaca2 and Mia-B1 (Figure 10A and B). Treatment of 0.5 µM DOX decreased
the number of viable cells in MiaPaca2 to 60% as compared to the control group (Figure
10A). Combination of DOX with BEZ caused significant reductions in cell viability
compared to individual drug treatments, decreasing from 34% with 50 nM BEZ to 22%
with 600 nM BEZ (Figure 10A). However, Mia-B1 cells responded quite differently when
treated in the same manner as MiaPaca2 cells. As expected, due to overexpression of
ABCB1 and similar to previous cell viability assays (Figure 2), cells treated with 0.5 µM
of DOX alone had no decrease in viability as compared to the control group. Also,
analogous to the results in Figure 5B which showed no increase in DOX accumulation, the
use of DOX in combination with 50 nM BEZ did not increase the effects on viability
compared to the cells treated with 50 nM BEZ alone (Figure 10B). Conversely, with
increasing concentrations of BEZ (i.e. 150, 300, 600 nM) in combination with DOX, there
was a corresponding significant decrease in the percentage of viable cells as compared to
all other groups (Figure 10B). Similar results were seen in the ovarian cancer cell lines
(Figure 10C and D). BEZ treatment alone decreased the percentage of viable cells
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remaining in both A2780 and A2780-dx cells to below 50%. The A2780 parental cells
were sensitive to DOX alone, with only 26% viable cells remaining after 48 hours of
treatment. Combination with BEZ further reduced viability to approximately 15% in all
groups, having shown little enhancement with increasing concentrations of BEZ (Figure
10C). In A2780-dx cells, similar to the results shown in Figure 2, 55% viable cells
remained after treatment with DOX alone. Combinations with BEZ reduced viability in a
dose dependent manner with approximately 15% viable cells remaining in the 600 nM
BEZ group (Figure 10D).
Cell viability is merely a measure of how many cells are still alive after treatment
and gives no information on whether a change is the result of reduced proliferation or
increased cell death. To determine the role that apoptosis plays in the observed decrease in
viability with combination treatment, cells were treated for 48 hours with BEZ and DOX,
either alone or in combination for use in western blot analysis. Treatment with BEZ alone
did not induce apoptosis (as measured by the extent of PARP cleavage) in any of the cell
lines tested (Figure 11). Treatment of MiaPaca2 and A2780 cells with DOX resulted in
PARP cleavage, which was enhanced with BEZ in a manner that mirrored the decrease in
viability (Figure 11A and B). In both the Mia-B1 and A2780-dx cells, DOX treatment
alone was unable to induce cleavage of PARP, while co-treatment with BEZ re-sensitized
the cells in a dose dependent manner that also mirrored the decrease in viability (Figure
11A and B). These results demonstrate that BEZ’s ability to inhibit ABCB1 can resensitize drug-resistant cells to DOX leading to a dose-dependent decrease in cell viability
and increase in apoptosis.
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Figure 10. BEZ235 (BEZ) re-sensitizes drug-resistant cells to doxorubicin (DOX).
Cells seeded into 96-well plates were treated with the indicated drug concentrations. After
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Promega. (A) MiaPaca2, (B) Mia-B1, (C) A2780, (D) A2780-dx. Data is plotted as mean ±
SD of replicates of 4. #, *, and ** indicate significance of the combination treatment group
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Figure 11. Effect of BEZ235 (BEZ) in enhancing doxorubicin (DOX)-induced
cytotoxicity. (A) MiaPaca2 and Mia-B1 cells were treated with increasing concentrations
of BEZ either alone or in combination for 48 hours. Cell lysates were collected and
analyzed using western blot. Apoptosis was determined by the presence of cleaved PARP.
(B) A2780 and A2780-dx were treated in a similar fashion and analyzed using western blot
for the presence of cleaved PARP.
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Effect of BEZ235 and doxorubicin on other ABC transporters
Several ABC transporters are overexpressed in cancer leading to multi-drug
resistant phenotypes, including ABCB1 (32, 34, 105). However, others play important
roles not only for xenobiotic clearance but also for transport of a wide range of substrates
across membranes throughout the cell (22, 34, 46, 91). Modulation of some of these
substrates by ABC transporters may influence the effectiveness of cancer drugs through
direct or non-direct interactions (22, 91, 106). Also, transporter expression levels may be
altered in response to drug treatment which could have an effect on treatment responses.
Therefore, mRNA expression levels of several ABC family transporters were assessed
using real-time quantitative PCR to test their responsiveness to treatment with BEZ and
DOX either alone or in combination in MDA-MB-231 breast cancer cells.
ABCB8 is a mitochondrial associated iron transporter which has been associated
with iron-mediated ROS formation of DOX (22). mRNA expression was induced by nearly
two-fold over control levels after and this effect was not enhanced when combined with
BEZ (Figure 12A). This response may act as a protective mechanism to reduce the amount
of ROS produced by the interaction of DOX with intra-mitochondrial iron.
The C branch of the ABC superfamily has the largest number of transporters
known to confer resistance to clinically relevant chemotherapeutics, including DOX (42,
45, 107-109). ABCC1 along with ABCB1 (measured but not included due to low
expression levels in these cells) and ABCG2 are the most common transporters associated
with multi-drug resistance to cancer treatment. However, in these cells, ABCC1 had no
response to DOX when treated alone and only a minimal, but significant, response was
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observed when combined with BEZ (Figure 12B). On the other hand, ABCC3, ABCC5,
and ABCC10 had small but significant increases in mRNA expression after treatment with
DOX (Figure 12C - E). Interestingly, ABCC3 had a large response to BEZ treatment alone
which was enhanced even more when combined with DOX (Figure 12C). ABCC5 and
ABCC10 both had responses that mirrored the treatment-related accumulations of
intracellular DOX. There was no change in expression in BEZ treated cells and significant
increases in expression over DOX alone when BEZ was combined with DOX (Figure 12D
and E).
As mentioned previously, ABCG2 is one of the three most commonly
overexpressed transporters related to multi-drug resistance (41). Therefore it was important
to also measure the mRNA expression levels of this protein. Similar to ABCC1, mRNA
expression of ABCG2 was not significantly altered after treatment with DOX (Figure 12F).
In addition, treatment with BEZ alone did not change mRNA expression. However,
ABCG2 mRNA expression was significantly increased when BEZ was combined with
DOX (Figure 12F).
These results suggest a differential response to BEZ and DOX treatment that is
likely cell line dependent. Currently, it is unclear how the changes in expression of these
transporters would affect the responsiveness of the cells to drug treatment or if BEZ would
also inhibit efflux mediated by these transporters. It is postulated that these responses are
protective mechanisms that would influence the effectiveness of drugs but further studies
are needed to confirm this.
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Figure 12. Modulation of ABC transporter transcript levels after treatment with
BEZ235 (BEZ) and doxorubicin (DOX). MDA-MB-231 cells were incubated for 24
hours in the presence of BEZ and DOX either alone or in combination. RNA was extracted
and mRNA transcript levels were measured using quantitative real-time PCR looking at
(A) ABCB8, (B) ABCC1, (C) ABCC3, (D) ABCC5, (E) ABCC10, AND (F) ABCG2.
Data is plotted as mean ± SEM of triplicates.
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Pancreatic Cancer
Effects of BEZ235 (BEZ) on enhancing doxorubicin (DOX)-induced cell killing
Survival signaling in the cell is commonly mediated by two closely interconnected
pathways which initiate at activated membrane bound receptors: the PI3K and RAS
pathways (64). Mutations result in overactivation of these pathways leading to not only
growth and survival advantages over the surrounding normal tissue but also reduced drug
effectiveness (110). Therefore, an important treatment strategy is to target these pathways
as a way of sensitizing the cells.
The dual kinase inhibitor, BEZ, targets the PI3K/AKT/mTOR pathway at multiple
nodes, inhibiting PI3K along with both complexes of mTOR (Figure 13). This could lead
to sensitization of cancer cells to cytotoxic agents like DOX. To examine this, MiaPaca2
cells were challenged with increasing concentrations of BEZ (50 nM to 600 nM) alone or
in combination with 0.5 μM DOX for 24hr. An increase in phosphorylation of AKT on
serine 473 (p-AKT 473) and threonine 308 (p-AKT 308) was observed at low
concentrations of BEZ with maximum effect occurring at 50 nM (Figure 14A). This is
most likely the result of a release of feedback inhibition of IRS1 through mTORC1
inhibition (Figure 13). At higher concentrations (150 nM - 600 nM), phosphorylation was
sequentially reduced with increasing concentrations of BEZ. Treatment with DOX alone
increased p-AKT 473 but not p-AKT 308, indicating a difference in the stress response to
DOX between PI3K and mTORC2. However, at both sites, the inhibitory effect of BEZ
was amplified when co-treated with DOX resulting in significant inhibition at the higher
doses. Phosphorylation of ribosomal protein S6 (S6), a downstream marker of mTORC1
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activity, was sensitive to BEZ treatment. Reduced phosphorylation was observed even at
the lowest concentration (50 nM) and remained inhibited in all treatment groups utilizing
BEZ (Figure 14).
BEZ235 enhances doxorubicin-induced apoptosis
Apoptosis was assessed using western blot analysis of the cleaved form of PARP (clPARP), a terminal step in the process involving the activation of caspase-3. BEZ alone had
no effect on PARP cleavage at any of the combinations tested in MiaPaca2 cells; however,
combination of BEZ with DOX induced a dose-dependent increase in apoptosis (Figure
14). The increase in cl-PARP corresponded to the level of AKT inhibition, which was
maximally inhibited at higher concentrations. In subsequent experiments, 300 nM BEZ
was used to achieve maximal inhibition of signaling while staying within the achievable
mouse plasma concentrations (78).

63

Figure 13. Schematic of BEZ235 (BEZ) inhibition. BEZ inhibits at multiple nodes,
including wild type and mutant forms of PI3K and both complexes containing mTOR.
Inhibition at various nodal points with BEZ reduces survival and growth signaling
downstream of PI3K and also prevents feedback activation by IRS1.
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Figure 14. BEZ235 (BEZ) decreases PI3K/mTOR signaling and sensitizes cancer cells
to doxorubicin (DOX). MiaPaca2 cells were treated for 24 hours with increasing doses of
BEZ (0, 50, 150, 300, 600 nM) alone or in combination with DOX (0.5 μM). PI3K
pathway signal transduction was assessed using western blot analysis to determine the
inhibitory effects of BEZ.
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Re-activation of AKT signaling does not reduce treatment efficacy
Our results indicated a release in feedback inhibition leading to activation of AKT
signaling (Figure 14). This could potentially diminish the effectiveness of combination
treatments with BEZ. Therefore, we used siRNA knockdown of PDK1 or Rictor to reduce
activation of AKT by PI3K and mTORC2, respectively. Knockdown of PDK1 with siRNA
resulted in reduced phosphorylation of AKT at threonine 308 compared to scrambled
siRNA (Figure 15). However, reduced AKT phosphorylation resulted in only minor
changes in apoptosis, as measured by PARP cleavage (Figure 15). Similarly, siRNA
knockdown of Rictor reduced AKT phosphorylation at serine 473 to near untreated control
levels (Figure 16). Again, very little change in apoptosis was observed between cells with
reduced mTORC2 activity compared to those with normal activity (Figure 16). These
results suggest that the transient inhibition of AKT survival signaling, which occurs at
earlier time points, is enough to sensitize the cancer cells to DOX before loss of feedback
inhibition through mTORC1 results in reactivation of the pathway.
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Figure 15. Phosphorylation of AKT by PDK1 does not reduce combination
effectiveness. MiaPaca2 cells were incubated with siRNA targeted towards PDK1 for 24
hours to knockdown protein expression. Cells were washed and treated as indicated with
BEZ and DOX for an additional 24 hours after which cell lysates were analyzed by
western blot.
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Figure 16. Phosphorylation of AKT by mTORC2 does not reduce combination
effectiveness. MiaPaca2 cells were incubated with siRNA targeted towards Rictor, a
subunit required for activation of mTORC2, for 24 hours to knockdown protein
expression. Cells were washed and treated as indicated with BEZ and DOX for an
additional 24 hours after which cell lysates were analyzed by western blot.
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BEZ235 enhances doxorubicin induced cell killing
We tested the hypothesis whether BEZ can potentiate the cell killing effects of
DOX in MiaPaca2, Capan-1 and CD18 cells. Cells were treated for 48 hours with 300 nM
BEZ and 0.5 μM DOX alone or in combination to measure the effects on
proliferation/viability and cell death. Cell growth was reduced by more than 40% after
treatment with DOX and nearly 70% following treatment with BEZ as compared to the
control (Figure 17A). The combination had an additive effect on proliferation, with
reduction in growth by 80% or more in all cell lines. Cell death (necrosis), as measured by
the trypan blue exclusion assay, was significantly increased after treatment with DOX in
all PDAC cell lines tested (Figure 17B). BEZ had marginal but significant effects
compared to control in MiaPaca2 cells while there was no significant increase compared to
control in Capan-1 or CD18 (Figure 17B). However, BEZ significantly increased the
percentage of cell death in all cell lines when combined with DOX (Figure 17B).
BEZ had little effect on apoptosis as assessed by PARP cleavage (Figure 18A and
B) in MiaPaca2 cells while it had modest effects in Capan-1 cells (Figure 18c and D). This
may indicate a greater dependence on the PI3K pathway in Capan-1 cells than MiaPaca2
cells. In either cell line, there was little observed apoptosis in cells treated with DOX
alone, showing only a slight cl-PARP band. However it was greatly enhanced when BEZ
was combined with DOX (Figure 18). Likewise, the TUNEL assay was used to assess
DNA fragmentation, another measure of apoptosis. Similar to PARP cleavage, apoptosis
was found to be significantly increased in cells treated with BEZ and DOX in combination,
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as shown by the representative images (Figure 19A) and corresponding quantification
(Figure 19B).
There were also dramatic effects on MiaPaca2 cell morphology after treatment with
BEZ and DOX. Using confocal microscopy and staining for actin (green), cleaved-PARP
(red), and DAPI (nucleus, blue), cells were visualized after 24 hours of treatment. DOX
treated cells are known to arrest mainly in the G2 phase of the cell cycle leading to an
increase in cell and nuclear size before committing to cell death and shrinking (Figure 20,
upper right panel). Intriguingly, despite causing very little cell death when treated alone,
BEZ does show an obvious phenotype which resembles cells after serum starvation. It is
known to arrest cells in the G1 phase leading to cells that are elongated and small (Figure
20, lower left panel). Cells treated with both BEZ and DOX were mostly small apoptotic
cells with fragmented nuclei (Figure 20, lower right panel). These same effects can also be
seen after 48 hours using phase contrast microscopy (Figure 21). There was a less obvious
change in morphology in CD18 cells, but they do seem to be enlarged with DOX treatment
and smaller with BEZ treatment similar to the changes seen in MiaPaca2 cells (Figure 22,
upper right and lower left panels). However, there is a dramatic change when cells are
treated with BEZ and DOX combined with most cells shriveled and dead (Figure 22, lower
right panel).
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Figure 17. PI3K/mTOR inhibition enhances doxorubicin (DOX) efficacy. (A) Cell
viability was measured using the MTS assay after 48 hours treatment of MiaPaca2, Capan1, and CD18 cells. Data is plotted as mean ± SEM of replicates of four. (B) Cell death
(necrosis) was measured using the trypan blue exclusion assay after 48 hours treatment of
MiaPaca2, Capan-1, and CD18 cells. Data is plotted as mean ± SEM of triplicates. p <
0.001 vs DOX, #p < 0.05 vs DOX.
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Figure 18. Combining BEZ235 (BEZ) with doxorubicin (DOX) enhances apoptosis in
pancreatic cancer. (A) Immunoblots of cl-PARP and actin in MiaPaca2 and (B) Capan-1
cell lysates after treatment for 24 hours
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Figure 19. Doxorubicin (DOX) mediated DNA fragmentation is enhanced with
BEZ235 (BEZ). (A) Apoptosis was assessed using the TUNEL assay after treatment for
24 hours. Representative images are shown with TUNEL positive nuclei stained green and
DAPI stained nuclei blue. (B) Quantification of TUNEL positive cells. Data is plotted as
mean ± SEM of replicates of four. #p < 0.05 vs DOX.
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Figure 20. Changes in cell morphology following treatment with BEZ235 (BEZ) and
doxorubicin (DOX). Representative confocal microscopy images of cell size and
morphology after treatment with BEZ and DOX. Actin is stained green (alexafluor 488)
and cl-PARP is stained red (alexafluor 555). Nuclei are stained with DAPI.
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Figure 21. Changes in morphology of MiaPaCa2 cells after treatment with BEZ235
(BEZ) and doxorubicin (DOX). Phase contrast representative images showing altered cell
morphology of MiaPaca2 cells after treatment.
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Figure 22. Changes in morphology of CD18 cells after treatment with BEZ235 (BEZ)
and doxorubicin (DOX). Phase contrast representative images showing altered cell
morphology of CD18 cells after treatment.
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Bcl-2 family proteins are modulated to induce caspase-dependent apoptosis following
treatment with BEZ235 and doxorubicin
The Bcl-2 family of proteins plays a major role in the induction of apoptosis for
both intrinsic and extrinsic pathways. Modulation of these proteins tips the balance to
favor either survival or death and could influence the effectiveness of treatments. Our
results showed that increases in mitochondrial associated pro-apoptotic protein expression
and caspase activation are required in enhancement of DOX-induced cell death with BEZ.
Apoptosis, measured by assessing PARP cleavage and DNA fragmentation, was enhanced
in cells treated with BEZ and DOX (Figure 18 and 19). Correspondingly, the Bcl-2/Bax
ratio was increased compared to control in cells treated with DOX indicating an activation
of the cells pro-survival response. This was normalized to control levels when DOX was
co-treated with BEZ (Figure 23A and B). BIM, an activator of Bax, has three splice
variants (BIM EL, L, and S) with the shortest form being the most cytotoxic. Expression of
the longest form of BIM (EL) was slightly enhanced with DOX treatment either alone or in
combination; however, treatment with BEZ, either alone or in combination, resulted in
robust expression of the smaller more cytotoxic forms of BIM (Figure 23C and D).
If enhanced expression of BIM and activation of Bax leads to caspase dependent
cell death (111), then caspase inhibition should diminish the effects of our combination
treatment. The caspase inhibitor, Z-VAD, was used to test the caspase dependence of
combination treatment. Treatment with Z-VAD reduced PARP cleavage after 24 hours of
treatment with only a minor band remaining in the combination treated cells (Figure 24A
and B). Caspase inhibition also resulted in a significant decrease in cell death in both the
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DOX and combination groups (Figure 24C), suggesting that increased expression of BIM
and activation of pro-apoptotic proteins, including Bax, are required for BEZ’s
enhancement of DOX-induced cell killing in pancreatic cancer cells.
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Figure 23. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on pro- and antiapoptotic proteins in pancreatic cancer cells. MiaPaca2 were treated with BEZ and
DOX alone or in combination for 24 hours of treatment and cell lysates prepared for
western blot analysis. (A) Immunoblots of Bcl-2, Bax, and actin. (B) Immunoblots of BIM
EL, L, and S.
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Figure 24. Role of Caspases in enhanced killing of pancreatic cancer cells with
BEZ235 (BEZ) and doxorubicin (DOX). MiaPaca2 cells were treated with BEZ and/or
DOX in the presence or absence of the caspase inhibitor Z-VAD. Cell lysates were
prepared for western blot after 24 hours of treatment. Cell death was assessed by the trypan
blue exclusion assay after 48 hours of treatment. (A) Western blot showing expression of
cl-PARP and actin. (B) Percent of dead cells are plotted. Data are plotted as mean ± SEM
of triplicates. *p < 0.001, #p < 0.05.
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Effect of BEZ235 and doxorubicin on colony formation
The colony formation assay measures a cells ability to retain cell proliferation and
growth potential, thereby escaping reproductive death after treatment with a cytotoxic
agent. This is important in that cells that escape reproductive death within tumors can
continue to grow leading to recurrences. MiaPaca2 cells, seeded in 10 cm plates, were
treated with BEZ and DOX either alone or in combination for four hours. Following
treatment, cells were washed, collected, and replated in 6-well plates at a density of 500
cells/well. After allowing colonies to form (~2 weeks), cells were stained and counted. The
increase in caspase-dependent cell death observed in cells co-treated with BEZ and DOX
corresponded with a significant reduction in colony formation as compared to cells treated
with DOX alone (Figure 25A and B). These results suggest that combining BEZ with DOX
could result in reduced recurrences due to loss of cell reproductive growth.
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Figure 25. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on colony formation.
MiaPaca2 cells were treated with BEZ and/or DOX for 4 hours then re-plated to allow
colony formation. After 2 weeks, colonies were fixed and stained with crystal violet. (A)
Representative dishes showing MiaPaca2 colonies. (B) Quantification of results. p < 0.001
vs DOX.
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BEZ235 does not enhance gemcitabine-induced cell killing
Gemcitabine (Gem) is the standard of care for pancreatic cancer patients and is
used either alone or in combination but has very little improvement in survival. In order to
obtain better clinical efficacy, new treatment strategies and combinations are needed.
Therefore we tested the effect of Gem with BEZ in MiaPaca2 cells to show whether this
combination was as effective as DOX and BEZ. Cell proliferation was assessed after 48
hours of treatment with BEZ either alone or in combination with 1 μM or 10 μM Gem. At
both concentrations, Gem alone reduced proliferation compared to the control. Similar to
DOX, the reduction in cell proliferation was enhanced when Gem was combined with BEZ
(Figure 26A). These results suggested that combination treatment with BEZ and Gem was
more effective than Gem alone. However, BEZ did not enhance the cytotoxic effects of
Gem, which is in contrast to the enhanced cell killing effect of the BEZ and DOX
combination as shown elsewhere. In fact, reduced trypan blue positive cells (Figure 26B)
and PARP cleavage (Figure 27) were observed with the combination treatment compared
to Gem alone. This was also evident visually, as the BEZ combination with Gem showed
no change compared to the BEZ alone at 24 or 48 hour time points (Figure 28). This is in
stark contrast to BEZ combination with DOX in MiaPaca2 and CD18 where the vast
majority of cells were dead (Figures 21 and 22).
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Figure 26. BEZ235 (BEZ) does not enhance Gemcitabine (Gem) toxicity in MiaPaca2
cells. (A) MiaPaca2 cell viability/proliferation was measured using the MTS assay after
treatment for 48 hours Data are plotted as mean ± SD of replicates of six. (B) Cell death
(necrosis) was measured using the trypan blue exclusion assay after treatment for 48 hours.
Data are plotted as mean ± SEM of triplicates. *p < 0.001 vs Gem alone, #p < 0.05 vs Gem.
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Figure 27. Effect of BEZ235 (BEZ) and Gemcitabine (Gem) on apoptosis. MiaPaca2
cells were treated for 24 hours with BEZ and/or Gem and cell lysates analyzed with
western blot. Note that cl-PARP is reduced when treated with the combination of BEZ and
Gem.
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Figure 28. Changes in cell morphology following treatment with Gemcitabine (Gem)
and BEZ235 (BEZ). MiaPaca2 cells were treated with BEZ and/or Gem and phase
contrast pictures were taken (A) 24 hours and (B) 48 hours later. Note that the morphology
of cells treated with the combination of BEZ235 and Gem is nearly identical to cells
treated with BEZ235 alone.
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BIM is not induced by gemcitabine when combined with BEZ235
To explore the possible cause for the contrasting results observed between Gem
and DOX combinations with BEZ, we determined the expression of the pro-apoptotic
protein BIM in MiaPaca2 cells. As shown previously, BEZ and BEZ in combination with
DOX induces robust expression of the smaller more cytotoxic splice variants of BIM
(Figure 23C and D, Figure 29). However, Gem alone had no effect on the expression of
any splice variant (Figure 29). Combinations of BEZ with Gem slightly reduced the
expression of BIM EL, which was similar to the effect observed with BEZ alone. Unlike
BEZ, the combination treatment induced very little expression of the smaller forms of BIM
(Figure 29). This finding is similar to the phenotypic observation that the combination cells
resembled the cells treated only with BEZ and further supports the hypothesis that BIM is
a major mediator of apoptosis in cells treated with BEZ and DOX.
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Figure 29. BIM expression following treatment with doxorubicin (DOX), BEZ235
(BEZ) and gemcitabine (Gem) in MiaPaca2 cells. MiaPaca2 cells were treated with BEZ
and/or Gem/DOX for 24 hours and cell lysates were prepared for western blot analysis.
Expression of BIM EL and BIM L, S. Note that BIM expression is not enhanced following
treatment with gemcitabine BEZ235 combination.
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BEZ235 increases DOX accumulation
To further understand the mechanism of enhanced cell killing with BEZ and DOX,
we considered the role of ABC transporters, which play a major role in the development of
multi-drug resistance and treatment failure (32-34, 103). In cancer cells with high
expression of ABC transporters, including ABCB1, intracellular drug accumulation is
reduced below the therapeutic threshold due to increased efflux. Interestingly, BEZ
enhanced accumulation of DOX, possibly through acting as a competitive inhibitor of the
substrate binding site, thereby blocking efflux of DOX (Figure 9). However, ABCB1
expression in MiaPaca2 cells is very low leaving the possibility that an increase in DOX
accumulation is not involved in the enhancement of efficacy when BEZ is combined with
DOX. Therefore, cells were treated for 24 hours after which cells were collected and DOX
accumulation measured. Interestingly, BEZ treatment nearly doubled the intracellular
concentration of DOX as compared to DOX alone suggesting that BEZ has effects on not
only ABCB1 but other transporters as well (Figure 30). We further investigated the impact
of increased intracellular DOX accumulation on DNA damage. Activation of DNA damage
response (DDR) proteins were visualized using western blot analysis. Cells treated with
DOX in combination with BEZ were associated with increased phosphorylation of the
DDR proteins ATM and chk2 compared to cells treated with DOX alone (Figure 31).
These results suggest that even in the absence, or low expression, of ABCB1, BEZ can still
cause increased accumulation of DOX likely through inhibition of one or more of the other
transporters associated with drug resistance leading to increased DNA damage and cell
death.
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Figure 30. Effect of BEZ235 (BEZ) on accumulation of doxorubicin (DOX) in
MiaPaca2 cells. MiaPaca2 cells were treated for 48 hours after which the cells were
collected and analyzed for DOX accumulation using a 96 well fluorescence plate reader.
Values are plotted as mean fluorescence over mg of total protein. Note that cellular
accumulation of DOX is enhanced with BEZ treatment. Data are plotted as mean ± SEM of
triplicates. *p < 0.001 vs DOX.
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Figure 31. Effect of BEZ235 (BEZ) and doxorubicin (DOX) in activation of DNA
damage response proteins. Western blots showing phosphorylation of DNA damage
response proteins ATM and chk2.
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BEZ235 potentiates DOX-induced inhibition of pancreatic tumor growth in vivo
We further evaluated the effects of BEZ, DOX, and Gem in a mouse tumor model.
In these experiments MiaPaca2 cells were implanted into the back flanks of female
Athymic nude mice and treating according to the protocol (Figure 32). DOX was injected
into the tail vein at a concentration of 10 mg/kg on day 1 and 15. Gem was given as an
intraperitoneal injection at a concentration of 100 mg/kg on day 1, 8, and 15. BEZ was
given by oral gavage every day at a concentration of 40 mg/kg for 28 days. Tumor
volumes were measured twice weekly throughout the study. Treatment with BEZ, DOX, or
Gem alone reduced tumor volume as compared to the control, although the difference did
not reach significance at any time point (Figure 33A). However, the combination of BEZ
and DOX resulted in a significant reduction of tumor volume compared to all other
treatment groups, as tumor volume was even depressed to below the initial volume until
day 35 (Figure 33A).
With DOX treatment, it is important to also assess toxicity as this is one of the dose
limiting factors for its use clinically. This is especially true when used in combination with
drugs that are known to inhibit key survival pathways. Change in body weight can be used
as a basic measure of overall toxicity in vivo because the amount of weight loss is related
to the extent of toxicity. Our results show that there was no significant difference in body
weights between the DOX and combination groups. Although there was some treatment
related weight loss associated with DOX whether given alone or with BEZ these changes
were similar throughout the study implying that the addition of BEZ did not enhance
toxicity (Figure 33B).
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Figure 32. Treatment protocol for mouse tumor studies. MiaPaca2 cells were injected
into athymic nude mice. Two weeks later, mice were randomized into the 5 groups to
receive the following drug treatments: 1. Control (no treatment); 2. Doxorubicin (DOX); 3.
BEZ235 (BEZ); 4. DOX+BEZ and 5. Gemcitabine (GEM). The dose and treatment
schedule for each drug is indicated in the protocol. On day 53, or when they reached
predetermined tumor volume endpoint, mice were sacrificed and tumors collected.
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Figure 33. BEZ235 (BEZ) potentiates doxorubicin (DOX)-induced inhibition of
pancreatic xenographs. (A) Tumor growth curves of athymic nude mice with MiaPaca2
xenographs treated with vehicle, DOX 10 mg/kg, BEZ 40 mg/kg, and gemcitabine (Gem)
100 mg/kg (n = 9). (B) Average body weights during the course of treatment. Data are
plotted as mean ± SEM from measurements of nine mice per group. αp < 0.01 and #p <
0.05 vs DOX.
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Breast cancer
BEZ235 inhibits PI3K pathway signaling and sensitizes MDA-MB-231 breast cancer
cells to doxorubicin
Breast cancer is the most diagnosed cancer and second leading cause of cancer
death in women. It frequently harbors mutations/deletions within the PI3K pathway or
hormone receptors that lead to overactivation of the PI3K pathway, helping to drive
tumorigenesis and drug resistance. Breast cancer treatment commonly includes DOX in its
regimens; however, it is frequently met with acquired or innate resistance leading to
failure. Therefore, we further investigated the effectiveness of combining BEZ and DOX in
the killing of breast cancer cells.
MDA-MB-231 cells were challenged with increasing concentrations of BEZ (50
nM to 600 nM) alone or in combination with 0.5 μM DOX. Cell viability was assessed 48
hours after treatment. All concentrations of BEZ along with the DOX treated cells resulted
in a near 50% reduction in viability as compared to untreated control (Figure 34).
Combination of BEZ with DOX led to a significant decrease in viability compared to the
individual drug treatments (Figure 34).
Cell lysates were prepared after 24 hours of treatment with BEZ and DOX for
analysis of PI3K and mTOR signaling with western blot. There was an initial increase in
activation of AKT, as shown by phosphorylation of serine 473, at the lowest dose of 50
nM (Figure 35), an effect likely resulting from the release of a feedback inhibition loop
through mTORC1. At the higher concentrations tested (150, 300, 600 nM), AKT activation
was reduced to below control levels. At all concentrations, mTORC1 activity was greatly
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reduced as compared to the untreated control. This decrease in signaling corresponded to a
dose-dependent increase in apoptosis, measured by assessing PARP cleavage (Figure 35).

97

MDA-MB-231
*p<0.001 vs BEZ alone
% viable cells

100

50

*

* * *

B

co
EZ ntro
B 50 l
EZ
nM
B 150
EZ
nM
B 300
EZ
n
60 M
D
0
D
O OX nM
X
D +B 0.5
O
X EZ M
D +BE 50
O
nM
X+ Z
1
B
5
D
O EZ 0 n
X+
M
B 300
EZ
n
60 M
0
nM

0

Figure 34. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on viability of MDA-MB231 breast cancer cells. Cells seeded into 96-well plates were treated with the indicated
concentrations of BEZ and DOX alone or in combination. After 48 hours, cell viability
was measured using the AQueous One cell viability assay kit from Promega. Note that cell
viability is significantly reduced with BEZ and DOX combination. Data are plotted as
mean ± SEM of replicates of six. *p < 0.001.
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Figure 35. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on PI3K/mTOR signaling
and PARP cleavage in breast cancer cells. MDA-MB-231 cells were treated with
increasing doses of BEZ (0, 50, 150, 300, 600 nM) alone or in combination with DOX (0.5
μM) for 24 hours. PI3K/mTOR signaling proteins (AKT, S6) and apoptosis were assessed
using western blot analysis. Note that BEZ decreases PI3K/mTOR signaling and sensitizes
breast cancer cells to DOX.
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BEZ235 inhibition is rapid and sustained in MDA-MB-231
There are several regulators of signaling along the PI3K pathway with some
leading to an active state allowing transmission of the signal while others promote an
inactive state to halt the transmission. We asked whether inhibition of PI3K and mTOR
signaling was an early event and how long its inhibition would be sustained in an in vitro
cell culture model. MDA-MB-231 cells were treated with BEZ and DOX, alone or in
combination, for 4, 8, 16, 24, and 48 hours. Cell lysates were prepared and analyzed using
western blot analysis. AKT inhibition occurred as early as 4 hours and was sustained for
up to 48 hours after initiation of treatment with BEZ either alone or in combination.
However, there is some reactivation of the pathway at the later time points, particularly 48
hours. Similarly, mTORC1 signaling was inhibited as early as 4 hours and sustained for up
to 48 hours (Figure 36).
These results demonstrate that the effect of BEZ on PI3K/mTOR signaling is rapid
and sustained for up to 48 hours in MDA-MB-231cell culture. This allows for continuous
depletion of survival signaling and increased sensitivity of cells to DOX.
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Figure 36. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on PI3K/mTOR
signaling. MDA-MB-231 cells were treated with BEZ and/or DOX and collected at
various time. Cell lysates were analyzed using western blot for AKT and S6 activation
after 4 to 48 hours of treatment. Note that PI3K pathway inhibition is rapid and sustained.
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BEZ235 increases doxorubicin accumulation in breast cancer cells
Previous results have shown that BEZ inhibits ABCB1 leading to increased
accumulation of DOX (Figures 6 and 7). Also, in MiaPaca2 cells, which have a low
expression of ABCB1, BEZ co-treatment with DOX leads to a two-fold increase in
accumulation as compared to DOX alone suggesting that BEZ inhibits other transporters
implicated in drug resistance. Here we test whether BEZ treatment in MDA-MB-231,
which also has low expression of ABCB1, will enhance accumulation over time. Cells
treated with DOX alone had an initial increase in accumulation at 4 and 8 hours which
quickly plateau showing little change from 16 to 48 hours (Figure 37, red bars). However,
cells treated with both BEZ and DOX had a steady increase in accumulation at each time
point (Figure 37, green bars). The 24 hour time points both show reduced accumulation for
unknown reasons.
In the absence of BEZ, the cells quickly reach equilibrium and are able to pump out
DOX as fast as it comes in. In the presence of BEZ however, DOX transport out of the cell
is reduced, never reaching equilibrium, allowing accumulation of the drug throughout.
Necrotic cell death was interrogated after 48 hours of treatment to determine its
association with DOX accumulation. BEZ and DOX individually had mild effects on cell
death (Figure 38A). However, there was a greater than additive increase in cell death
(Figure 38A) with combination treatment that also mirrored the increase in DOX
accumulation (Figure 38B).
These results strongly suggest that BEZ enhances the effects of DOX in MDA-MB231 cells by not only inhibition of PI3K survival signaling, but also through a time
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dependent increase in DOX accumulation. Moreover, since MDA-MB-231 cells express
little ABCB1, BEZ likely acts as an inhibitor to one or more of the other ABC transporters
involved in drug resistance indicating that it may be useful in a wide range of cancer types.

MDA-MB-231 time course

103

Relative fluor/mg

6

4

2

0

l
r
r
r
r
r
r
r
r
r
r
ro 4h 8h 6h 4h 8h 4h 8h 6h 4h 8h
t
1 2 4
1 2 4
on OX OX X X X OX OX X X X
C D D O O O D D O O O
D D D Z+ Z+ +D +D +D
E E Z Z Z
B B BE BE BE

Figure 37. Effect of BEZ235 (BEZ) on doxorubicin (DOX) accumulation in breast
cancer cells.

DOX fluorescence was measured at various time points to see the effect of

BEZ on accumulation over time using a 96 well fluorescence plate reader (ex. 485, em.
595). Note that BEZ enhances time-dependent accumulation of DOX in MDA-MB-231
cells. Data are plotted as a single measurement to demonstrate the time-dependent nature
of DOX accumulation.
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Figure 38. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on cell death in MDAMB-231 cells. Cells were treated with BEZ and/or DOX for 48 hours and cell death was
quantified using the trypan blue exclusion assay. DOX accumulation was quantified by
directly measuring DOX fluorescence in a 96 well fluorescence plate reader (em. 485, ex.
595). (A). Percent of dead cells; (B). DOX accumulation. Note that BEZ enhances cell
death and also causes increased accumulation of DOX in MDA-MB-231 cells. Data are
plotted as mean ± SEM of triplicates. #p < 0.05, *p < 0.001.
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Colony formation in MDA-MB-231 cells is depleted with combination treatment
Our results have shown that combination treatment significantly reduces colony
formation in pancreatic cancer (Figure 25). Here we interrogate the effect of combination
treatment with BEZ and DOX on reducing colony formation in breast cancer cells. MDAMB-231 cells were treated with BEZ and DOX either alone or in combination for four
hours. Following treatment, cells were washed, collected, and re-plated in 6-well plates at a
density of 500 cells/well. The colonies were allowed to form for ~2 weeks after which they
were stained and counted. Colony formation was significantly reduced to less than 10
colonies per well in cells treated with the combination treatment of BEZ and DOX as
compared to DOX alone (Figure 39). Individual DOX treatments did reduce colony
formation but still allowed approximately 40 colonies per well to growth which could
potentially lead to faster time to recurrences clinically. BEZ treatment alone had no effect
on colony formation as compared to control. This supports the need for the addition of a
cytotoxic agent like DOX to treatment regimens based on targeted agents, such as BEZ’s
use in KRAS mutant MiaPaca2 and MDA-MB-231 cells.
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Figure 39. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on colony formation in
breast cancer cells. MDA-MB-231 breast cancer cells were treated with BEZ, DOX or the
combination of both drugs for 4 hours and then re-plated to allow colony formation. After
2 weeks, colonies were fixed, stained with crystal violet, and counted. Note that the colony
formation is significantly reduced with combination treatment. Quantification of results.
Data are plotted as mean ± SEM of triplicates. αp < 0.01 vs DOX.
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Effect of combination treatment with BEZ235 (BEZ) and doxorubicin (DOX) in cells
with PI3K activating mutations
Mutations to PI3K and PTEN (or deletions to PTEN) are some of the most
common events in cancer which lead to pathway over-activation. There have been several
agents which target proteins along this pathway developed for use as anti-cancer drugs,
including BEZ. Our results have shown that BEZ has dramatic effects in enhancing DOX
efficacy in KRAS mutant cancers. Here we examined whether BEZ can enhance the effects
of DOX in PI3K mutant breast cancer cells. Mcf-7 cells were treated with BEZ and/or
DOX for 24 or 48 hours. The results show that DOX itself had minimal effects on cell
viability whereas BEZ reduced cell viability whether it was treated alone or in combination
with DOX (Figure 40A). It is noteworthy that DOX did not enhance the effects of BEZ and
there were a slightly higher number of viable cells compared to BEZ alone. Furthermore,
necrotic cell death was unaffected by DOX treatment while BEZ itself resulted in a
significant increase (Figure 40B). Again, while there was a significant increase in cell
death with the combination treatment over BEZ alone, the effects were minimal (Figure
40B) despite the fact that there is nearly double the amount of DOX accumulated within
the cells (Figure 40C). There was a slight increase in AKT phosphorylation on serine 473
with DOX treatment. On the other hand, AKT activation was completely inhibited with
BEZ treatment whether treated alone or in combination with DOX (Figure 41). Similar
results were observed with inhibition of mTORC1 activity as S6 phosphorylation was
dramatically reduced with BEZ treatment. However, while there was little effect on
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apoptosis with DOX, BEZ strongly induced PARP cleavage that was enhanced very little
with the addition of DOX (Figure 41).
These results suggest that cell lines which have an activating mutation within the
PI3K/mTOR pathway would not have a significant benefit from the addition of DOX to
BEZ.
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Figure 40. Effect of BEZ235 (BEZ) and doxorubicin (DOX) in PI3K mutant breast
cancer cells. PI3K mutant Mcf7 cells were treated with BEZ and/or DOX for 48 hours
after which cell viability was measured using the MTS assay. Cell death was measured
using the trypan blue exclusion assay. DOX accumulation was quantified by directly
measuring DOX fluorescence in a 96 well fluorescence plate reader (em. 485, ex. 595).
(A) Cell proliferation. Data are plotted as mean ± SEM of replicates of four. (B) Cell death
and (C) DOX accumulation. Data are plotted as mean ± SEM of triplicates. Note that Mcf7
cells did not have significant benefit from the addition of DOX to BEZ. *p < 0.001, #p <
0.05.
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Figure 41. Effect of doxorubicin (DOX) and BEZ235 (BEZ) on survival signaling in
Mcf7 cancer cells.

Mcf7 cells were treated with BEZ and/or DOX for 24 hours and cell

lysates analyzed using western blot for PARP cleavage, AKT and S6 activation. Note that
survival signaling is depleted with BEZ235 but had little effect in apoptosis when treated
alone or in combination
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Other solid tumors
BEZ235 enhances the effectiveness of doxorubicin against colon and lung cancer
Our results have shown that combining BEZ with DOX can significantly increase
treatment effectiveness compared to the single agents in pancreatic cancer and KRAS
driven breast cancer. KRAS mutations, along with mutations or deletions in P53, are also
common in other cancers, including those of the colon and lung. Therefore, we sought to
test the combination effectiveness in these cancer types as well.
Colon (HCT 116) and lung (H1299) cancer cells were grown in 10 cm plates and
treated with BEZ and DOX either alone or in combination for 24 or 48 hours. Cell lysates
were assessed for apoptosis (cl-PARP) and PI3K pathway activation (p-AKT and p-S6)
using western blot analysis. The phosphorylation at serine 473 of AKT was reduced
following treatment with BEZ regardless of its use in combination with DOX in HCT 116
cells (Figure 42A). S6 phosphorylation was also considerably reduced with BEZ treatment,
although when combined with DOX it is slightly less efficient (Figure 42A). Combination
with BEZ enhanced PARP cleavage (apoptosis) and a significant increase in necrosis as
compared to DOX alone (Figure 42A and B). Furthermore, similar to pancreatic cancer,
the increase in cell death following treatment with BEZ and DOX paralleled a significant
increase in DOX accumulation with BEZ suggesting an important role for ABC transporter
inhibition in the enhancement of DOX efficacy (Figure 42C).
Similar results were observed in the H1299 cells. Apoptosis and necrosis were both
enhanced in the combination treated cells compared to those treated with BEZ or DOX
alone. This corresponded to a reduction in PI3K pathway signaling with BEZ treatment
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and a significant increase in DOX accumulation when BEZ was combined with DOX
(Figure 43).
Pancreatic cancer is predominantly driven by KRAS mutations with mutations or
deletions in P53 also common. These results demonstrate that other cancer types which
harbor mutations in KRAS (HCT 116) and P53 (H1299) can also be sensitized to DOX
when combined with BEZ indicating the potential for benefits to a wide range of cancer
types.
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Figure 42. Effect of BEZ235 (BEZ) and doxorubicin (DOX) in KRAS mutant colon
cancer. HCT-116 cells were treated with BEZ, DOX or in combination for 24 hours. Cell
death was measured using trypan blue exclusion assay after 48 hours of treatment. DOX
fluorescence was measured after 24 hours of treatment using a 96 well fluorescence plate
reader. (A) Immunoblots of cl-PARP, p-AKT 473, AKT, p-S6, S6, and actin. (B) Percent
cell death (C) Dox accumulation. Note that BEZ enhanced the effects of doxorubicin in
KRAS mutant colon cancer cells. For B and C, Data are plotted as mean ± SEM of
triplicates. *p < 0.001 vs DOX.
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Figure 43. Effect of BEZ235 (BEZ) and doxorubicin (DOX) in P53 mutant lung
cancer cells. H1299 lung cancer cells were treated with BEZ, DOX or in combination for
24 hours. Cell death was measured using trypan blue exclusion assay after 48 hours of
treatment. DOX fluorescence was measured after 24 hours of treatment using a 96 well
fluorescence plate reader. (A) Immunoblots of cl-PARP, p-AKT 473, AKT, p-S6, S6, and
actin (B) Percent cell death (C) Dox accumulation. Note that BEZ enhanced the effects of
doxorubicin in p53 mutant lung cancer cells. For B and C, Data are plotted as mean ± SEM
of triplicates. *p < 0.001 vs DOX.
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Cardiotoxicity
Effects of BEZ235 combination with doxorubicin on rat myoblast cytotoxicity
Cardiotoxicity, which may ultimately lead to heart failure, is the main dose limiting
factor for clinical use of DOX clinically (86, 112). Moreover, combination therapies using
inhibitors of growth factor signaling with DOX show increased cardiac dysfunction (95,
113-115). One major factor of this could be because the inhibitors, like the monoclonal
HER2 antibody trastuzumab, block at the initiating node upstream of both RAS and PI3K
(Figure 44). This effectively stops all survival signaling downstream of these receptors
making the cells, including cardiac cells, susceptible to treatment with cytotoxic agents,
including DOX. Therefore, we examined the effects of combining BEZ with DOX in an
undifferentiated rat myoblast cell line (H9C2) for in vitro studies of DOX cytotoxicity.
Cells were treated for 48 hours with DOX and BEZ either alone or in combination after
which expression of apoptotic proteins and cell death were assessed. DOX treatment
significantly increased dead cells compared to control. However, combination treatment
did not enhance cell death and in fact, resulted in reduced cell death (Figure 45).
The ratio of the pro-survival protein Bcl-2 over the pro-apoptotic protein Bax is
used as a measure of apoptosis in cells, with an increase over control favoring cell survival.
The Bcl-2/Bax ratio was increased nearly threefold with BEZ treatment, alone or in
combination, an effect which was not seen with DOX treatment alone (Figure 46).
Interestingly, the shorter forms of BIM had increased expression with DOX treatment
while all splice variants were dramatically reduced after combination treatment (Figure
47). This is in stark contrast to the increased expression observed in the pancreatic cancer
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cells and supports the previous results in H9C2 cells showing reduced cell death compared
to DOX treated cells.
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Figure 44. Schematic of trastuzumab effects on cell signaling. Trastuzumab is a
monoclonal antibody against HER2. Binding of this antibody to HER2 receptor reduces
signaling through both RAS and PI3K to cause reduced survival and growth in the cancer
cell. Combinations using trastuzumab and DOX have been reported to cause increased
cardiac toxicity (95, 113-115).
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Figure 45. Cell death is reduced in H9C2 cells with co-treatment of BEZ235 (BEZ)
with doxorubicin (DOX). Cell death (necrosis) was measured in using the trypan blue
exclusion assay after treatment either alone or in combination with the indicated
concentrations of BEZ and DOX for 48 hours. Data are plotted as mean ± SEM of
triplicates. #p < 0.05 vs DOX.
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Figure 46. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on Bcl2/Bax expression in
H9C2 cells. Immunoblots of Bcl2, Bax and actin from H9C2 cell lysate after treatment
with BEZ and DOX either alone or in combination with the indicated concentrations for 24
hours. Note that the Bcl-2/Bax ratio is significantly higher with BEZ and BEZ+DOX as
compared to control and DOX treatment groups.
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Figure 47. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on BIM expression in
H9C2 cells. Immunoblots of BIM EL, BIM L, S, and actin from H9C2 cell lysate after
treatment with BEZ and DOX either alone or in combination with the indicated
concentrations for 24 hours. Note that BIM expression is lost when BEZ is combined with
DOX.
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Effect of BEZ235 on doxorubicin-induced Cardiac Dysfunction
The major dose-limiting factor for the use of DOX clinically is cardiotoxicity
leading to heart failure (116, 117). We evaluated the effects of combination therapy on
cardiac function by echocardiography after completion of the treatment schedule (28 days)
in the tumor-bearing mice (Figure 48). DOX treatment caused a significant decrease in
systolic function as assessed by measuring fractional shortening. Systolic function in mice
treated with BEZ alone or in combination with DOX was not significantly different than
untreated controls (Figure 49A and C). In addition, left ventricular diastolic function as
assessed by the E/A ratio was not significantly different among the 4 groups (Figure 49B).
To further interrogate why BEZ does not enhance the cardiotoxic effects of DOX,
mice were treated with 5 mg/kg DOX and 40 mg/kg BEZ either alone or in combination.
Twenty four hours later, whole heart lysates were for western blot analysis. There was
increased activation of both AKT and ERK in the hearts with combination treatment which
was not observed in the DOX or BEZ treated mice (Figure 50). With BEZ treatment, there
is a loss of feedback inhibition through IRS1 leading to reactivation of PI3K. More
importantly, transient inhibition of PI3K re-directs signaling into the RAS pathway leading
to increased survival signaling through ERK, which includes phosphorylation and
degradation of BIM (Figure 51).
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Figure 48. Treatment protocol for mouse cardiotoxicity studies. MiaPaca2 cells were
injected into athymic nude mice. Two weeks later, mice were randomized into the
following 4 groups to receive the following drug treatments: 1. Control (no treatment); 2.
Doxorubicin (DOX); 3. BEZ235 (BEZ); and 4. DOX+BEZ. The dose and treatment
schedule for each drug is indicated in the protocol. On day 28, echocardiography was
performed to measure systolic and diastolic heart function using VEVO700
echocardiography system.
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C

Figure 49. Cardiac function following treatment with BEZ235 (BEZ) and
Doxorubicin (DOX) treatment in tumor bearing mice. Cardiac function was assessed
by echocardiography 28 days after treatment in tumor bearing mice. (A) Systolic function,
(B) diastolic function, and (C) Representative M-mode images from Control, DOX, BEZ
and BEZ+DOX. #p < 0.05 vs control. Note that combining BEZ with DOX does not
enhance cardiotoxicity. Data are plotted as mean ± SEM from measurements of nine mice.
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Figure 50. Effect of BEZ235 (BEZ) and doxorubicin (DOX) on survival signaling in
the heart. c57 mice were treated with DOX and BEZ alone or in combination for 24
hours. The mice were sacrificed, hearts collected, and tissue lysates prepared. Western
blots were performed for expression of AKT and ERK.
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Figure 51. Possible mechanisms of cardioprotection with BEZ235. BEZ inhibits both
AKT and mTOR leading to reduced downstream survival and growth signaling. Inhibition
of mTORC1 releases a feedback inhibition loop through IRS1 leading to re-activation of
PI3K and AKT. Signaling through the RAS pathway is also enhanced leading to ERK
activation. ERK is an important mediator of survival signaling in the heart and may also
influence the expression levels of BIM, a downstream target.
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CHAPTER 4: Discussion

ABC transporters
BEZ235 inhibition of ABCB1
A major cause of treatment failure in cancer patients is overexpression of one or
more of the ABC-type transporters which lead to a multi-drug resistance phenotype by
reducing intracellular concentrations of drug to below their therapeutic threshold (32, 33).
The most commonly overexpressed transporter in cancer is ABCB1, which is known to
confer resistance against several clinically used drugs, including etoposide, paclitaxel,
vincristine, and doxorubicin (105). Since the early 1980’s, there have been studies
investigating the use of ABCB1 inhibitors clinically, but results so far have been
underwhelming (32-34). Our data demonstrates that BEZ increases accumulation of DOX
in ABCB1 overexpressed drug resistant cells, but has a less dramatic effect on
accumulation in drug resistant cells with undetectable levels of ABCB1. Moreover, at the
nanomolar concentrations used in this study, BEZ does not inhibit the ATPase activity of
ABCB1 and is, at most, a very weak substrate. Additionally, this data demonstrates that
BEZ is able to re-sensitize ABCB1 overexpressing cells to DOX treatment in a
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concentration dependent manner. For the first time, our results suggest that BEZ has the
potential to reverse the MDR phenotype in cancer cells overexpressing ABCB1.
Cancer cells with overexpression of one or more of the ABC transporters have
reduced intracellular accumulation of cytotoxic agents to levels below the effective dose
due to their increase in efflux capacity (32-34). Inhibitors of these transporters prevent
cellular efflux, resulting in enhanced intracellular concentrations of the cytotoxic agent and
improved efficacy. Our results show that treatment of ABCB1 overexpressing cells,
A2780-dx and Mia-B1, with BEZ in combination with DOX for 48 hours increase the
intracellular concentration of DOX to levels nearing those of their respective parental cell
lines. However, the PI3k/mTOR pathway plays an important role in signaling and protein
translation, so it is conceivable that BEZ increases accumulation of DOX by other means
besides direct inhibition of the transporter. Along those lines, rapamycin, an inhibitor of
mTOR complex 1, increases accumulation of vincristine and DOX in drug resistant
lymphoma cell lines, at least in part through the down regulation of ABCB1 protein
expression (101). To address the possibility of expression change of ABCB1, we
demonstrate that BEZ can inhibit the efflux capacity of ABCB1 overexpressing cells using
a shorter treatment time of three hours (one hour co-treatment of BEZ and DOX), to a
similar extent as that previously shown with 48 hours treatment. This makes it unlikely that
there would be any meaningful reduction in the levels of ABCB1 expression over the time
frame of the experiment. Similar results are described for the PI3k inhibitor LY294 002,
where treatment for 0.5 hours and 24 hours did not change the resulting effect on drug
accumulation, which was concluded to be indicative of a substance that did not change
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ABCB1 expression (118).These studies are more in line with our results, which indicate
that BEZ inhibits ABCB1 function without decreasing its expression.
Several kinase inhibitors, including sildenafil and sunitinib, reverse the MDR
phenotype of cells overexpressing ABC transporters through interaction at the substrate
binding site (50, 54). These compounds not only bind, but are substrates themselves, as
shown by their capacity to enhance ATPase activity in isolated membranes overexpressing
ATP transporters. BEZ, on the other hand, has very little effect on ATPase stimulation in
isolated p-gp membranes whereas the positive controls verapamil and sildenafil
significantly enhance activity. Furthermore, BEZ is still able to inhibit downstream mTOR
signaling in all drug resistant cell lines to the same extent as their respective parental cell
lines. This would not be expected if BEZ were a favorable substrate because there would
be reduced accumulation within the cell leading to a muted response.
BEZ inhibits PI3k and mTOR through binding at the ATP binding cleft suggesting
the possibility that it inhibits ABCB1 in a similar fashion (78). However, our results
indicate that BEZ does not inhibit ABCB1 function through inhibition of ATP hydrolysis
since it is unable to prevent verapamil mediated stimulation of ATPase activity. These data
suggest that in the nanomolar range, BEZ mediated inhibition of ABCB1 efflux is not
through competitive inhibition at the ATP binding site and is not likely to be a competitive
substrate inhibitor. Our results are similar to those of LY294 002, which also does not
involve direct interaction with the substrate binding site (118). Moreover, a highthroughput screening assay measuring ABCB1 mediated calcein AM efflux was used to
identify BEZ as a substrate inhibitor of ABCB1 (119). In contrast to our results, the
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concentrations of BEZ used to inhibit calcein AM efflux were in the micromolar range,
with several of the studies using 20 µM. It has been shown that plasma levels of BEZ in
mice peak at 1.68 µmol/L 30 minutes after an oral gavage feeding of 50 mg/kg and rapidly
decrease from there (78). We believe that in vitro concentrations below 1 µM would be
more translatable to a clinical setting making our finding that BEZ inhibits ABCB1 in the
nanomolar range important.
Over expression of ABC transporters in cancer cells can lead to a decrease in drug
accumulation and treatment failure. Therefore, it is essential for an inhibitor to be able to
re-sensitize overexpressed cells to treatment with a cytotoxic agent like DOX. Our results
show that BEZ reduces the viability of ABCB1 overexpressing cells when co-treated with
DOX in a dose dependent manner (Figure 10). We also show that this reduction in viability
is the result of a corresponding increase in apoptosis, shown by increases in the cleaved
form of PARP (Figure 11). Other reports have shown that BEZ can enhance the
cytotoxicity of a drug, even when treatment with BEZ alone only had minimal effects on
cell death (120-124). It has been said that this enhancement of cytotoxicity is due to
inhibition of survival signaling within the PI3k and mTOR pathways. While to a degree
this is correct, especially in cells with amplified signaling within these pathways, our data
suggests that this enhancement of toxicity is also the result of increased accumulation of
the drug due to inhibited ABCB1 mediated efflux. Further studies are necessary to reexamine to what extent increased accumulation of these cytotoxic agents in combination
with BEZ plays in the enhancement of cytotoxicity. Phosphorylation of ABCB1 also plays
a role in the efficiency of substrate transport (125). It cannot be ruled out that a change in
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phosphorylation state of ABCB1 is occurring after treatment with BEZ since we are also
manipulating an important signaling pathway involved in the activation of several kinases.
It is conceivable that a decrease in efflux efficiency could occur without a decrease in total
protein levels through inhibition of a kinase upstream ABCB1.
Somewhat surprising was that DOX appears to be a weak substrate for ABCB1
despite it being widely known that DOX resistance in tumors is, in part, mediated by
overexpression of ABC transporters (109). In pancreatic cancer, which is known to be
resistant to drug treatment, even patients without preoperative chemotherapy were shown
to have ABCB1 expression rates of more than 50% (40). Also, treatment with DOX
selects for drug resistant clones which overexpress ABCB1 indicating that these
transporters may be the best option for protection against this drug. In spite of this, our
results indicate that DOX is not an ideal substrate for ABCB1. This may explain the
discrepancy between our studies with DOX, a weak substrate, and the previous report with
calcein AM (119), likely a much better substrate for ABCB1. This highlights the
importance of selecting the correct cytotoxic agent when seeking to enhance its efficacy
through inhibition of ABCB1 transport.
Traditional ABCB1 inhibitors are known to have associated toxicities due to
decreased systemic clearance of anti-cancer agents, which needs to be considered when
using ABC transporter inhibitors (33). There are currently more powerful inhibitors being
tested that have greater specificity to particular ABC transporters, however there remains
the possibility that the clinical benefit will not be great even with this increase in
specificity (33). This is because substrate redundancy makes the therapeutic window

132
extremely narrow for inhibitors specific to one transporter. We propose another alternative
to circumvent toxicity associated with co-treatment of ABC transporter inhibitors with
anti-cancer drugs. For those drugs which are weak substrates, like DOX, it may be more
beneficial to combine them with drugs that themselves have anti-cancer activity along with
being weak or non-substrate inhibitor, like BEZ. This may prove to be a beneficial strategy
at attacking both ABCB1 negative as well as ABCB1 overexpressing cancer cells leading
to improved outcomes for wide range of patients.
Treatment related induction of ABC transporter mRNA
While ABCB1 was the first discovered and is one of the best studied ABC
transporters, it is not alone in conferring multi-drug resistance. There is a significant
amount of redundancy between the transporters of which several are implicated in
resistance to a wide range of cancer drugs (32, 34). Moreover, ABC transporters which do
not have a direct role in cancer drug efflux may still mediate their efficacy and/or toxicity.
Change in efflux transporter expression could also have major implications on a drug’s
effectiveness over time. Therefore, it is important to address the effects of a drug on
expression of multiple multi-drug resistance related and unrelated transporters.
Along those lines, ABCB8 does not directly transport DOX but still could have
implications on DOX anti-cancer effects as well as cardiotoxicity (22, 106). In MDA-MB231 cells, ABCB8 expression is induced with DOX treatment. This is important because
ABCB8 confers resistance that is specific to DOX in melanoma cells by protecting the
mitochondrial genome (106). Other studies using genetic deletion of ABCB8 in mice
demonstrate that it is a mitochondrial iron transporter, and loss of expression causes
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mitochondrial iron accumulation, increased ROS production, and cell death (22). These
studies suggest that ABCB8 expression confers resistance to DOX through export of
mitochondrial iron leading to a reduction in ROS production and mitochondrial genome
stability while its inhibition results in enhanced cytotoxicity not only in cancer cells but
normal tissues as well. It remains to be seen what impact the increase in expression
observed in MDA-MB-231 cells would have on DOX. Mitochondrial iron is important in
DOX-mediated ROS production therefore the increase in transcription is likely a protective
response of the cell. In addition, since combination with BEZ does not increase ABCB8
mRNA expression compared to DOX, and based on our results that BEZ inhibits ABCB1
to induce intracellular DOX accumulation, it does not appear that DOX concentration
alone determines transcript levels. On the other hand, this gene may have a low rate of
transcription such that DOX alone causes the cell to reach its max rate of transcription so
that the addition of more DOX has no effect. Further studies are needed to elucidate this as
well as determine whether the increased expression observed in breast cancer cells is
ubiquitous or tissue specific.
There are several ABC transporters that illicit drug resistance to cancer therapies.
ABCC1 is involved in resistance to drugs as well as inflammatory responses mediated by
leukotrienes (126, 127). However, ABCC1 has low expression in MDA-MB-231 cells and
DOX treatment did not affect ABCC1 mRNA expression in these cells. BEZ co-treatment
with DOX did cause a significant increase in transcript levels however the increase was
minor and not likely to have an effect on protein levels or drug efficacy.
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ABCC3 is another member of the ABCC subfamily known to confer resistance to
anti-cancer drugs. Gene expression is induced after 24 hours of DOX treatment in MDAMB-231 cells, although the response was minimal and not likely to alter protein
expression. On the other hand, BEZ alone stimulates a nearly four-fold increase in ABCC3
transcript levels while combinations with DOX increase expression nearly six-fold. This
dramatic induction of the gene with BEZ implies a regulatory role of the PI3K pathway on
ABCC3. In neuroblastoma cells, ABCC3 expression is directly negatively regulated by
MYCN through associating with the core promoter region and repressing transcription
(126). It has also been shown that active GSK3 reduces MYC protein expression through
phosphorylation of threonine 58 which leads to protein degradation (128, 129). Therefore,
BEZ could reduce MYC protein expression by its inhibition of AKT activity which frees
repression of GSK3. The reduction in MYC protein would then release its inhibitory
function on ABCC3 resulting in an increase in expression.
The impact of such an increase in expression remains unclear. ABCC3 is important
in bile acid transport along with chemotherapeutic agents (126). It is upregulated in nonsmall cell lung cancer and used as a marker for multi-drug resistance (42). Interestingly,
the ABCC subfamily has been shown to confer resistance to Gem but ABCB1 and ABCG2
had little involvement when tested with differing ABC transporter inhibitors (45).
Correspondingly, our results demonstrate that BEZ enhances the effects of DOX but not
Gem in pancreatic cancer cells. Increased expression of ABCC3 due to BEZ treatment
could play a major role in these conflicting results. Furthermore, whereas it may have a
negative impact on cancer treatment if overexpression in cancer cells reduces intracellular
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concentrations of the drug, we speculate that BEZ treatment could have beneficial effects
in other diseases that rely on elimination of bile acids, such as cholestasis which use the
export of bile acids and glucuronides by ABCC3 as an alternative route of export (127). In
depth expression analysis after treatment with BEZ is needed to confirm a change in
transcript levels in other normal tissues, like the liver.
Two other members of the ABCC subfamily implicated in chemoresistance are
ABCC5 and ABCC10. Expression of both transporters after treatment with DOX is
significantly increased while they are increased even more in combinations with BEZ.
These results parallel the increase in intracellular concentration of DOX observed breast,
pancreatic, colon and lung cancer cells. In other studies, ABCC5 transfected cells were
shown to confer increased resistance to DOX and nucleoside analogs like 5-fluorouracil
(109) while ABCC10 is a broad specificity transporter of xenobiotics, including taxanes
and vinca alkaloids (130). Interestingly, ABCC5 is a cGMP transporter which is expressed
in the heart and could, along with phosphodiesterase 5 (PDE5), be involved in the
regulation of intracellular levels of cGMP and its possible paracrine effects (131). In
support of this, PDE5 and ABCC5 have similar affinities for cGMP, and PDE5 inhibitors
have been shown to also inhibit ABCC5 (132). In cancer, ABCC5 is increased in cervical
cancers during growth as well as breast cancer metastasis to the bone (107, 133). The
reason behind the upregulation remains unknown but it is speculated that ABCC5 reduces
intracellular levels of cGMP thereby relieving its inhibitory effects on cell growth.
However, this remains inconclusive as one study found no effect on cell proliferation when
ABCC5 was knocked down in breast cancer cells (107).
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Unlike ABCC5, ABCC10 does not transport cGMP or cAMP but does have a
physiological role in the transport of leukotrienes (44, 130). In cancer, ABCC10 is
implicated in resistance to vinca alkaloids and is the only other ABC transporter besides
ABCB1 that has been shown to confer resistance to taxanes (102). Our results show a
responsiveness of ABCC5 and ABCC10 to DOX at the level of transcription but it is
unlikely that this will have any effects on efficacy since DOX is a poor substrate for the
ABCC subfamily. Moreover, it is unknown what effect BEZ might have on the efflux
capacity of these transporters. Since BEZ is an ATP-binding pocket inhibitor it would be
easy to surmise that it would at least be a weak substrate for ABCC5 and/or ABCC10.
ABCG2, along with ABCB1 and ABCC1, is among the most frequently
upregulated genes associated with cancer drug resistance. Similar to the results for the
ABCC subfamily, ABCG2 seems to be responsive to the intracellular concentrations of
DOX. This suggests a protective response of the cell to mitigate the damage brought on by
DOX exposure. ABCG2 is known to mediate resistance to several anti-cancer therapies
including DOX (41, 100, 134-137). However, a mutation at arginine 482 is necessary for
transport of anthracyclines (41, 135) therefore protein overexpression does not necessarily
translate into a reduction in DOX efficacy. Furthermore, although there is no evidence of
inhibition of ABCG2 efflux by BEZ, several other inhibitors of PI3K pathway kinases do
interact with ABCG2 to modulate its function (100, 136). Therefore, considering that BEZ
seems to modulate one or more ABC transporters other than ABCB1, we speculate that
ABCG2 inhibition is involved in the enhancement of DOX accumulation.
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ABC transporters have an important role in cancer multi-drug resistance and
anticipating changes in expression with cancer therapy can help clinicians develop better
treatment regimens to maximize the effects of a given therapy. Post-treatment expression
profiles can also open the door to novel uses for a drug that would not have otherwise been
known. Extensive research is needed to determine if the changes in expression observed in
our studies can be realized in other cancer and disease models.

Cancer
Pancreatic cancer
Pancreatic cancer is a devastating disease which has a death rate nearly as high as
the incidence rate (138). Current treatment options for pancreatic ductal adenocarcinoma
(PDAC), which is the most common form of pancreatic cancer as well as the most deadly,
have an extremely limited benefit to patients. In the present study, we show that inhibition
of the PI3K/mTOR pathway with BEZ sensitizes pancreatic cancer cells to DOX, but not
Gem, both in vitro as well as in an in vivo mouse tumor model. The enhanced sensitivity to
DOX-induced killing of pancreatic cancer cells is in part due to down regulation of
translational and survival signaling downstream of PI3K, including AKT. In addition, we
observe increased ROS formation and intracellular accumulation of DOX, which likely
occurs through inhibition of one or more of the ABC-type transporters, a family of proteins
necessary for the elimination of xenobiotics, including DOX (32, 139). As a result,
combinations with BEZ cause enhanced activation of DNA damage response proteins and
modulate the levels of pro- and anti-apoptotic proteins to favor induction of apoptosis
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(Figure 30 and 31). Interestingly, similar enhancement in killing was observed in breast,
lung, and colon cancer cell lines (Figures 38, 42, and 43) providing evidence that this
combination could be beneficial to multiple solid tumor types. Also, our results
demonstrate that BEZ does not enhance the cell killing effect of Gem, which is the
standard of care for pancreatic cancer patients. Clinically, cardiac dysfunction is the major
dose-limiting factor for the use of DOX in patients with cancer. Our results show that
treatment of DOX along with BEZ does not increase the cardiotoxic effects of DOX both
in vitro and in vivo despite inhibition of the PI3K pathway, which is critical in protecting
the heart from stress (140). These confounding results may involve the severe reduction in
expression of the pro-apoptotic protein BIM when combining BEZ and DOX in the in vitro
cardiomyocyte studies. These results suggest new possibilities of combining PI3K/mTOR
inhibitors with traditional cytotoxic agents, including DOX, to achieve better control of
PDAC.
The classical RAS pathway, which transmits signals through RAS to the
extracellular-signal related kinase (ERK), demonstrates an important target for treatment of
PDAC; however, there have been few successes to date (141). Due to the high degree of
crosstalk, as well as overexpression of one or more receptor tyrosine kinases (RTKs), there
is also a high prevalence of enhanced activation of the PI3K/mTOR pathway (142).
Moreover, activation of AKT has been associated with poor outcomes of PDAC patients
(143), and there is also evidence that RAS mediates its oncogenic initiation and
maintenance through PI3K/PDK1 (58). Therefore, targeting the PI3K/mTOR pathway also
represents a potential treatment strategy in PDAC.
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Supporting the evidence that RAS drives tumorigenesis in PDAC through PI3K, a
previous report has shown that dual inhibition of PI3K and mTOR with BEZ is equally
sensitive in both KrasG12D and PI3K (p110αH1047R) driven PDAC cells (144). However, our
current results and other studies demonstrate that BEZ reduces proliferation but does not
induce a significant amount of cell death (145, 146), which may lead to earlier progression
of tumors in patients. Therefore, combination therapy utilizing a cytotoxic agent, like
DOX, could greatly enhance the clinical utilization of BEZ and possibly other PI3K
pathway inhibitors. Previous studies in breast and ovarian cancer have shown that
inhibiting the PI3K pathway significantly enhances DOX cell killing (110, 147). Studies
utilizing similar combinations in PDAC are limited because PDAC is not a primary
indication for DOX. This is because of resistance mechanisms toward DOX which include
not only activation of survival signaling but also enhanced drug elimination via the ABC
transporters and reduced drug delivery (148) leading to intracellular concentrations below
the therapeutic threshold. However, our results show that DOX could be a very effective
therapeutic for treatment of PDAC when combined with the correct secondary agent to
overcome resistance. Therefore, this strategy needs to be evaluated in the future.
BEZ treatment for extended periods in MiaPaCa2 cells leads to re-activation of the
PI3K pathway and phosphorylation of AKT, likely through inhibition of mTORC1 causing
a release of feedback inhibition through IRS1, suggesting an enhancement of survival
signaling that could result in treatment failure. However, siRNA knockdown of PDK1 and
Rictor to specifically prevent phosphorylation of AKT downstream of PI3K and mTORC2
respectively, demonstrates that reactivation of AKT does not reduce the effectiveness of
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using BEZ in combination with DOX (Figure 15 and 16). This suggests that the transient
inhibition of AKT survival signaling, which occurs at earlier time points as previously
described (120, 149), is enough to sensitize the cancer cells to DOX before loss of
feedback inhibition through mTORC1 results in reactivation of the pathway. This has also
been shown by others who demonstrate that BEZ induces P53 independent apoptosis
despite reactivation of AKT in MYC-driven lymphoma cells (150). Furthermore, the dose
required for BEZ to prevent reactivation of the AKT pathway seems to be cell line
dependent as other cell lines failed to show such an effect.
Our results demonstrate that PI3K/mTOR inhibition does not enhance the cell
killing effect of Gem. Other studies report that BEZ and Gem have anti-proliferative
effects, which is enhanced with combination treatment (145, 151); although, high
concentrations of BEZ (10 μM) fail to improve apoptosis (145, 151). We also observe
inhibition of proliferation with either BEZ or Gem in MiaPaca2 cells which is further
reduced with combination treatment (Figure 26). Surprisingly, these results do not translate
into increased cell death, and the combination is even less effective as compared to Gem
alone (Figure 26). As previously discussed, BEZ treatment causes a significant increase in
expression of the ABC transporter ABCC3, which is known to confer resistance to Gem
(45). Increased expression of this protein could lead to reduced intracellular
concentrations, and thus effectiveness, of Gem but not DOX explaining the discrepancy.
This suggests that the type of cytotoxic agent employed can play a major role in its
effectiveness when combined with PI3K pathway inhibitors. It is also likely that not all
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PI3K or dual PI3K/mTOR inhibitors will have similar effects on DOX enhancement in
PDAC and other cells due to the unique properties of BEZ.
In mouse studies, combination treatment with BEZ and DOX significantly reduces
tumor size compared to all other groups (Figure 33). This increased efficacy could be due
to combination of reduced proliferation and survival signaling concomitant with increased
DOX accumulation, ROS formation, and BIM expression. PDAC tumors have a unique
tumor microenvironment known for their extensive buildup of stroma called desmoplasia
that results in tumors with reduced vasculature and intratumoral hypoxia which makes
tumors extremely resistant to drug treatment (6, 148). Our tumor model using MiaPaca2
xenographs in immunocompromised nude mice likely does not resemble the tumor
microenvironment of PDAC patients clinically for several reasons, but most glaringly,
because of a lack of immune response cells infiltrating the tumor. Therefore, it is unknown
whether accumulation of drugs clinically would be sufficiently enhanced to reach levels
needed for a therapeutic response. However, by targeting multiple resistance mechanisms
that reduce survival signaling through PI3K and inhibit ABC efflux transporters, we are
able to maximize the effects of the drug combination that we believe would be more
effective than the current standard of care.
In summary, our results provide compelling evidence that combining BEZ with DOX
is highly effective in killing pancreatic cancer cells in vitro and reducing tumor size in
vivo. In contrast, BEZ does not enhance the effects of Gem which is the standard of care
for PDAC suggesting that combinations with DOX would be more effective than current
treatment standards. Moreover, BEZ treatment does not exacerbate DOX induced cell

142
death in vitro or contractile dysfunction in tumor bearing mice signifying there would be
minimal increase in the cardiotoxic effects with combination therapy. Mechanistic
investigations reveal that BEZ enhances the effects of DOX in cancer cells through down
regulation of PI3K signaling, increased ROS generation, altered expression of BIM, and
improved DOX accumulation. Based on these results, we propose that combining BEZ
with DOX could be an attractive clinical option for patients suffering from PDAC.
Breast cancer
Breast cancer is the most common malignancy in American women, with an
estimated 231,840 new cases diagnosed in 2015 (4). Treatments include surgery, radiation,
and anti-cancer drugs, including cytotoxic agents and targeted therapies. Since its
discovery more than 30 years ago DOX has remained a first-line anti-neoplastic drug for
the treatment breast cancer. However, treatment related toxicities and acquired drug
resistance limit the effectiveness of this drug and others. Therefore, combination therapies
which target resistance mechanisms in the tumor and allow for reduced cumulative doses
are greatly needed. Here we provide evidence that BEZ enhances the effects of DOX in a
manner that is dependent on the mutation type of the cell. In KRAS mutant MDA-MB-231
cells, combinations with BEZ enhance the efficacy of DOX in a time- and dose-dependent
manner increasing apoptosis and necrosis in a manner that parallels the increase in
intracellular DOX accumulation (Figures 35-38). Moreover, colony formation is
significantly reduced with combination treatment of MDA-MB-231 cells. On the other
hand, PI3K mutant Mcf7 cells do not benefit to the same extent from combining BEZ with
DOX. Cell viability, cell death, and apoptosis are only marginally affected by combination
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treatment (Figures 40 and 41). The reason for this discrepancy is likely due to the reliance
of the cells to a particular pathway, and in this case, the PI3K pathway.
Activating mutations along the PI3K/AKT/mTOR pathway are the most frequently
occurring mutations in breast cancer and help to drive tumor initiation and maintenance
(152, 153). They also provide a promising target in the treatment of breast cancer, as
demonstrated by the number of inhibitors being developed which target this pathway
(153). However, beneficial responses to these drugs are cell line dependent and there is
acquired resistance associated with treatment due to upregulation of alternative survival
pathways, including ERK, MYC, and RSK (73). Likewise, our results and others show that
PI3K wild-type and KRAS mutant MDA-MB-231 cells are resistant to BEZ treatment
while PI3K mutant Mcf-7 cells are sensitive (154-156). This demonstrates the
dependencies of these cells on the PI3K pathway for survival highlighted by the
observation that MDA-MB-231 cells are resistant despite a similar level of reduction in
PI3K pathway activation. Also in MDA-MB-231, inhibition of both AKT and S6 occurs as
early as four hours after treatment and is sustained for at least 48 hours (Figure 36).
Therefore, the effects on the PI3K pathway are not the cause of resistance to BEZ. For that
reason, combination therapies, including those using cytotoxic agents like DOX, are
looked upon to provide better treatment responses over a wide range of tumors and
mutation types. Our results demonstrate that combining BEZ with DOX improves the
outcome over single agent treatments in MDA-MB-231 cells. These results are similar to
our observations in PDAC cells, an outcome that may be correlated to an activating
mutation in KRAS. Conversely, while DOX alone had minimal effects in Mcf-7 cells, BEZ
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is extremely effective on its own and the addition of DOX does not have a profound effect
on cell death and apoptosis. In light of this, we speculate that combination therapy using
BEZ and DOX may be most beneficial in cells which do not have an activating mutation
along the PI3K pathway.
Our data demonstrates the anti-proliferative effects of BEZ on breast cancer cells
irrespective of the mutation status of the cells. This is similar to previous reports in breast
and other cancer cell lines which show that BEZ induces a strong G0/G1 arrest leading to
reduced proliferation (78, 145, 146, 156). However, the reduction in proliferation does not
always correlate with increased cell death. Induction of cell death by BEZ is dependent on
the mutation and/or expression status of the cell, with those harboring activating mutations
to PI3K or overexpressing HER2 being the most sensitive to treatment while KRAS
mutant and PTEN deleted cells being resistant (156). Despite the relative resistance of
KRAS cells to BEZ, there is still dependence on this pathway, especially in times of stress
as shown with our combination with DOX. Similar to PDAC, induction of BIM may be
important in this sensitization. BEZ is known to increase mRNA and protein expression of
BIM in ovarian cancer cells (80) as well as transcriptionally through a mechanism
involving FOXO3A, which is inhibited by AKT (146).
Resistance to chemotherapy is often mediated by the expression of one or more
ABC-type transporters (32, 34, 105). Likewise, our results indicate that BEZ inhibits
ABCB1 which can re-sensitize drug resistant cells to DOX. However, increased
accumulation of DOX is observed in cells which do not express a high amount of ABCB1
protein, like MiaPaCa2. Similarly, neither MDA-MB-231 nor Mcf-7 cells express ABCB1

145
to a great extent (157), but still show enhanced accumulation of DOX when combined with
BEZ. This reiterates the fact that BEZ likely inhibits other ABC transporters besides
ABCB1. Surprisingly, unlike what is observed in MDA-MB-231 cells, the increase in
DOX accumulation only results in a small enhancement of cell death in Mcf-7 cells. It’s
possible that BEZ alone is effective enough in cells addicted to the PI3K pathway that the
addition of another cytotoxic agent is not needed. On the other hand, in vivo results would
provide a better understanding of how well BEZ works as a single agent. The addition of a
cytotoxic agent like DOX may provide a better overall response in these cells by inducing
a longer lasting effect, rather than the transient effects that would be expected due to the
metabolism and elimination of the drug.
Colon and lung cancer
Lung and colon cancer represents the first and third leading cause of cancer death
in the United States, respectively (4). Both types commonly express mutations or deletions
to KRAS, EGFR, and P53 which help to drive tumorigenesis as well as resistance to
therapeutics (158, 159). The PI3K pathway is also frequently deregulated leading to
several inhibitors of this pathway, including BEZ, being tested for use as monotherapy or
in combination (158-164). Our results demonstrate that BEZ can enhance the effects of
DOX in HCT 116 colon cancer and H1299 lung cancer cells resulting in more apoptosis
and cell death (Figures 42 and 43). Similar to pancreatic and breast cancers, DOX
accumulation was also increased in these cell lines. These results reveal the wide ranging
potential for combining BEZ with DOX in the treatment of cancer.
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Similar to our results in breast cancer, BEZ reduces PI3K and mTOR signaling to
below control levels in both colon and lung cancer cells (Figures 42 and 43). However,
BEZ alone induces little cell death indicating these cells can easily bypass this pathway to
induce alternate survival mechanisms. This is not unexpected considering HCT 116 harbor
KRAS activating mutations along with its mutations in PI3K while H1299 has wild type
KRAS and PI3K. Our results in breast and pancreatic cancer and other reports using cell
lines without activating mutations in PI3K have shown a similar resistance to BEZ (154156). Interestingly, BEZ does have anti-proliferative effects against HCT 116 cells which
can lead to a significant reduction in tumor growth in a mouse xenograph tumor model
(165, 166). This is likely the result of BEZ’s ability to arrest the cell cycle and not from an
increase in cell death which could potentially lead to an early time to recurrence. However,
BEZ combinations with DOX significantly increase cell death which corresponds to
increased cleavage of PARP, a marker for apoptosis. Enhancement of cell death along with
reduced proliferation offers a better therapeutic impact than either drug treated alone.
Drug resistance mediated by the overexpression of one or more ABC transporters is
a major clinical problem (32, 33). At least one transporter is overexpressed in most if not
all resistant cancer cells, including HCT 116 and H1299 (167, 168). Our results
demonstrate that BEZ can enhance DOX accumulation by approximately two fold over
DOX alone in both cell lines which corresponds to the observed increase in cell death
(Figure 42 and 43). It is likely that this sensitization is dependent on both decreased
survival signaling along with increased drug delivery, which in turn results in an
enhancement of DNA damage and cell death. BEZ has previously been shown to increase
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irenotecan effectiveness in HCT 116 cells through its inhibition of the PI3K pathway
(166). Likewise, BEZ overcomes gefitinib-acquired resistance through down-regulation of
the PI3K/mTOR pathway in lung cancer (169). We hypothesize that in addition to its
inhibitory effects on the PI3K pathway, BEZ may also enhance drug accumulation of
irenotecan and gefitinib to further enhance the combinations effects. Previous reports have
shown that sorafinib, a platelet-derived growth factor receptor (PDGFR) and vascular
endothelial growth factor receptor (VEGFR) inhibitor, can inhibit ABCG2 and overcome
resistance to irenotecan in colorectal cancer (168), demonstrating that irenotecan is a
substrate for at least one ABC transporter. We have shown that BEZ inhibits ABCB1 but
that there are likely other targets. It’s not hard to presume from BEZ’s enhancement of
irenotecan and sorafinib overcoming ABCG2-induced resistance to irenotecan that one of
the other transporters inhibited by BEZ is ABCG2. Further studies in cell lines
overexpressing ABCG2 are needed to confirm this but the overall implications of these
results along with our previous studies in other cancer types could be substantial.

Cardiotoxicity
Cancer patient survival is continuing to improve with the advent of more
efficacious therapies that lead to better overall survival. According to the SEER cancer
statistics review, with breast cancer alone, the NCI estimates that approximately 2.6
million women diagnosed with cancer were alive in 2008. However, several therapies
used in the treatment of cancer can cause serious health risks, including cardiovascular
events leading to heart failure which many times do not become apparent until years later
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(170). This is especially true in cases where combination therapies utilizing anthracyclines
and receptor tyrosine kinases are used. In HER2 positive breast cancer, the humanized
monoclonal antibody trastuzumab inhibits HER2 signaling resulting in clinical responses
that are enhanced with the addition of DOX, as shown in a pivotal phase III clinical trial
(97). However, combination treatment in these patients was associated with unacceptably
high rates of New York Heart Association class III/IV cardiotoxicity resulting in all large
adjuvant trials only evaluating sequential dosing strategies despite the improved anticancer effects of co-treatment (113). In light of this, we assessed the cardiotoxic effects of
combining BEZ, an inhibitor that targets a pathway downstream of HER2, with DOX in
both in vitro and in vivo models. Our results show that cell death is reduced with
combination treatment with BEZ and DOX compared to treatment with DOX alone in
H9C2 rat myoblast cells. The reduction in cell death is associated with an increase in the
Bcl-2/Bax ratio as a result of decreased Bax expression, as well as loss of BIM expression.
Both of these events signal a pro-survival response in the cell that helps mitigate the
cytotoxic effects of DOX. Moreover, the effect on cardiac function in tumor bearing mice
treated with DOX is not potentiated with the addition of BEZ (Figure 49). Also, our results
show that mouse hearts treated with a single dose of DOX and BEZ display increased
survival signaling through AKT and especially ERK (Figure 50). These results suggest that
combining an inhibitor of the PI3K pathway with DOX will not cause an increase in
cardiac toxicity leading to heart failure.
This observation is potentially significant given the negative effects associated with
trastuzumab and anthracycline co-administration. There are some key differences in
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signaling between uses of trastuzumab that could explain this. It targets an initiating node
(HER2) that transmits extracellular signals into the cell causing a host of events that play
key roles in cell proliferation, growth, and survival among others (171). This reduces
signaling through the PI3K and RAS pathways, both of which are important for survival
signaling in the heart through inhibition of several pro-apoptotic proteins, including Bax,
BIM, and BAD (172). Inhibition using trastuzumab releases the inhibitory effects on these
pro-apoptotic proteins leaving cardiomyocytes susceptible to damage after treatment with
DOX. HER2 also has important roles in heart development and function. This is
demonstrated by the report that HER2 knockout mice develop cardiomyopathy consistent
with dilated cardiomyopathy (173). Moreover, inhibition of HER2 with trastuzumab itself
causes cardiotoxicity in 4-7% of patients highlighting its necessary role in normal cardiac
function (113, 170).
Our results also show that treatment with BEZ alone displayed no significant
changes in H9C2 cell death or cardiac function which is in line with our biochemical
assessment of pro-apoptotic protein expression (Figures 45-47 and 49). Interestingly, when
combined with DOX in vitro, there is reduced cell death as compared to DOX alone
consistent with the decrease in BIM protein expression (Figures 45 and 47). This is
opposite to the increased expression observed with combination treatment in pancreatic
cancer. As yet, the mechanism underlying the differential regulation of BIM protein
expression is unknown, although both AKT and ERK play important roles in both its
transcriptional and post-translational regulation (174-177). BIM is transcriptionally
regulated by the nuclear localization of FOXO3A. FOXO3A in turn is regulated by
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inhibitory phosphorylation by AKT, which mediates its exclusion from the nucleus and
interaction with the protein 14-3-3 ultimately leading to degradation (176, 177).
Theoretically, treatment with BEZ should relieve the inhibitory phosphorylation on
FOXO3A promoting its nuclear localization and transcription of BIM. This anticipated
result is observed in our cancer cells which help to promote cancer cell death. However,
the decrease in BIM expression after treatment with BEZ in H9C2 cells is likely related to
the alternate regulatory pathway through ERK. Whereas BEZ treatment inhibits
PI3K/mTOR pathway activation, it causes an increase in activation of the ERK pathway
(178) resulting from redirection in signaling away from PI3K. BIM is a direct target of
ERK and its phosphorylation promotes ubiquitination and degradation of the protein (174,
175). Therefore, it is likely that in H9C2 cells, the redirection of signaling into the RAS
pathway leads to increased activation of ERK and consequently, a reduction in BIM
protein.
Other contradictory reports have shown a role for ERK in DOX-induced cell death
and cardiomyopathy (179-181). The reason for this discrepancy may be due to the
difference in DOX concentration and route of administration. In H9C2 and HK-2 (kidney)
cells, 1 μM or higher concentrations of DOX were used to show an increase in ERK
phosphorylation and that this increase was in part responsible for apoptosis induction (179,
180). Although these plasma concentrations are achievable, it is at the higher end of a steep
bell curve that likely is not sustained for long periods of time. An alternate explanation for
the increased activation of ERK in these situations is that at higher concentrations, or more
cytotoxic stress, the protection incurred by ERK gives way and switches to a pro-death
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cascade that is not observed at lower concentrations of DOX. Also, the mouse
cardiotoxicity studies used intraperitoneal (IP) injections of high concentrations of DOX
(181). In our experience, IP injection of DOX causes a host of gastrointestinal issues that
more closely resemble a model of inflammation. It is possible that the reduced function
observed in the hearts of these mice was a result of septic shock and organ failure.
In tumor bearing mice, DOX results in a significant reduction in systolic function
four weeks after the initialization of the treatment. However, unlike with combinations
containing trastuzumab, the addition of BEZ did not augment the cardiotoxicity. Similar to
the studies with H9C2 cells, the reason for this may be due to increased survival signaling
through ERK. Heart cell lysates, collected 24 hours after treatment, displayed increased
phosphorylation of both AKT and ERK. Although it needs to be confirmed, we
hypothesize that BIM expression in this situation is also decreased leading to a protective
effect on the heart. In addition, inhibition of mTORC1 with rapamycin protects the heart
against ischemia-reperfusion injury through activation of JAK2/STAT3 (99). Likewise,
inhibition of mTORC1 with BEZ could mediate a cardioprotective effect against DOX in
conjunction with the enhancement of other survival pathways.
Our results suggest that BEZ induces a cardioprotective effect against DOX in the
heart through enhanced activation of the ERK survival signaling pathway. This results in a
corresponding ERK-dependent decrease in BIM expression that mediates the decreased
cardiotoxicity. Therefore, we believe that this could have major implications on the use of
this combination treatment in the clinic.
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CHAPTER 5: Study Limitations
Our results provide evidence of the beneficial effects of combining BEZ with DOX
to treat cancer which does not also enhance the cardiotoxic effects of DOX. However,
there are several aspects of inhibiting the PI3K/mTOR pathway in combination with DOX
that could not be addressed in this study that remain important in the effects of this
combination. Many of these processes relate to the activation level of the PI3K pathway
with several being specific to mTOR. Autophagy is a process that utilizes cellular catabolic
degradation of intracellular organelles, cytoplasm, and proteins to maintain metabolic rates
when undergoing stress (182). It is also predominantly under the control of mTORC1
which down-regulates its activity through phosphorylation of unc-51-like autophagy
activating kinase 1 (ULK1) (183). Under nutrient rich conditions, the PI3K/mTOR
pathway is activated resulting in inhibition of autophagy. Conversely, when the cell is
deprived of nutrients or cellular energy levels are low, autophagy is activated in order to
maintain metabolites to the cytoplasm where they are reused as a source of energy or to
provide building blocks for the synthesis of new molecules (183). Autophagy is initiated
through a multi-protein complex containing ULK1, FIP200 (RB1-inducible coiled-coil 1),
autophagy-related 13 (ATG13), and ATG1 which is under the control of mTORC1 (184,
185). Furthermore, nucleation of the phagophore requires a second complex containing
vacuolar protein sorting 34 (VPS34 or PIK3C3) and Beclin1 which can recruit various
different proteins that regulate autophagy (185). This includes covalent attachments of
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ATG5 to ATG12 and phosphatidylethanolamine to microtubule-associated protein 1 light
chain 3 (LC3) (184). This process, along with the recruitment of several other ATG
proteins, allows for growing of the membrane to enclose the cellular contents in the
completed autophagosome. The autophagosomes then fuse with lysosomes with the help of
lysosomal-associated membrane protein 2 (LAMP2) and RAB7A to form autolysosomes
which degrade the engulfed components (184-186).
Autophagy not only has important regulatory functions in normal cells, but also has
important functions in tumor initiation and promotion (187). However, there are
conflicting roles for autophagy in cancer with evidence of it also acting as a tumor
suppressor. Similarly, autophagy is thought to act as a pro-survival mechanism for cancer
cells which can lead to drug resistance (185). In light of this, BEZ could result in enhanced
autophagic response that could delay commitment to cell death. Paradoxically, others have
shown that autophagy is an important pathway that is necessary for the pro-death
mechanisms of rapamycin (185). Studies which utilize knockdown of key autophagy
proteins, including Beclin1, ATG5, and ATG7, would be beneficial to elucidate the role
that autophagy has in the enhancement of cell death when BEZ is combined with DOX. In
addition, autophagosome formation utilizing LC3-GFP constructs transfected into cells
would help determine the extent of autophagy induction after short and long term drug
treatments. These important studies could help elucidate the opposite effects towards
combination treatment that was observed in cancer cells as compared to H9C2 cells.
Moreover, BIM has been shown to inhibit autophagy through its anchoring of Beclin1 to
microtubules (188). Therefore, since BEZ inhibits mTOR activity and BIM expression is
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induced (at least in cancer cells) it seems as though autophagy is being acted on through
opposing signals. These aforementioned studies would interrogate the role that autophagy
plays with the combination of BEZ and DOX in cancer and heart cells.
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Figure 52. Autophagy initiation and maturation. Autophagy is primarily controlled by
mTORC1 through its regulation of a complex containing ULK1. Upon loss of signaling
through mTORC1, inhibition of ULK1 is relieved allowing for nucleation and initiation of
autophagy. Maturation requires the recruitment of several ATG protein complexes and
many other proteins including Beclin1 and LC3 which allows for elongation of the
autophagosome and engulfment of organelles and other cytoplasmic components.
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In addition to down-regulating autophagy, increased BIM expression is likely to
mediate an apoptotic response through its inhibition of pro-survival proteins. Our results
suggested a correlation of such an effect with enhanced cell death observed in cancer cells
while loss of BIM expression corresponded to reduced cell death in H9C2 cells. However,
further studies are needed to confirm the role of BIM in mediating the effects of BEZ and
DOX. Apoptosis is initiated through two separate but interconnected pathways termed the
intrinsic and extrinsic pathways that are dependent on activation of caspases (189-191).
The extrinsic pathway involves the activation of death receptors and formation of deathinducing signaling complexes (DISC) which include pro-caspase 8 that is subsequently
cleaved into its active form (189). Active caspase 8 can then either act on downstream
caspases to directly induce an apoptotic response or can cleave another Bcl-2 family proapoptotic protein, Bid, to form the active truncated form of Bid (t-Bid) which translocates
to the mitochondria and acts as an amplifier of the apoptotic signal (189). The intrinsic
pathway is characterized by activation of pro-apoptotic Bcl-2 family proteins Bax and Bak
which induce mitochondrial membrane permeablization and release of cytochrome-c,
Smac/DIABLO, apoptosis inducible factor (AIF), and endonuclease G (192). Bax and Bak
are activated by BH3 only members of the Bcl-2 family, including BIM, Bid, Bad, PUMA,
and NOXA, and inhibited by the anti-apoptotic members, Bcl-2, Bcl-xL, and Mcl-1 (193).
Cytochrome-c release initiates the formation of the apoptosome and subsequent activation
of caspases 9 and 3 to trigger execution of cell death (192).
Our results in cancer imply the activation of Bax and Bak through increased
expression of BIM. However, confirmatory experiments are needed. If BIM is important in
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the enhancement of cell death mediated by treatment with BEZ and DOX, then knockdown
should significantly reduce the effects of combination treatment. Likewise, BIM induces
its apoptotic response through activation of Bax and Bak, therefore knockdown of these
proteins individually or together should dramatically reduce effectiveness of treatment.
Moreover, the extrinsic pathway of apoptosis could be involved in the induction of cell
death. Therefore, experiments utilizing inhibition of this pathway, either through the use of
caspase 8 inhibitors or through overexpression of FADD-like interleukin-1 β-converting
enzyme-like protease (FLICE)-inhibitory proteins (FLIP) should be performed to
determine the extent of extrinsic pathway involvement.
Our results showed that Z-VAD nearly completely abrogated PARP cleavage.
However, while there was a significant decrease in cell death, there remained a large
percentage of cells that were not protected. This suggests an alternate mode of cell death
induction. AIF is released after mitochondrial membrane permeablization along with
cytochrome-c and induces caspase independent cell death (194, 195). Likewise, cell death
induced by treatment of BEZ and DOX may depend on caspase dependent and
independent mechanisms, including AIF release, toxic autophagy, and
necrosis/necroptosis.
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Figure 53. Extrinsic and Intrinsic apoptosis pathways. (A) Extrinsic apoptosis initiates
through activation of death receptors and processing of pro-caspase 8 within the DISC to
active caspase 8 through a process which is inhibited by FLIP. Caspase 8 can directly
activate downstream caspases or cleave the pro-apoptotic protein BID to form tBID which
translocates to the mitochondria to amplify the apoptotic signal. (B) Intrinsic apoptosis is
characterized by activation of pro-apoptotic proteins Bax and Bak through a process
mediated by relieving of the inhibitory functions of one or more anti-apoptotic proteins
(Bcl-2, Bcl-xL, Mcl-1) by BH3 only proteins, including BIM. Activation of Bax and Bak
allows for dimerization and mitochondria permeability allowing for release of cytochromec and AIF into the cytoplasm mediating both caspase dependent and independent
apoptosis.
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CHAPTER 6: Conclusions

Our results suggest that BEZ in combination with DOX could potentially be an
attractive clinical option for patients with a range of cancer types. This conclusion is based
on our results showing enhanced anti-cancer efficacy which does not augment the
cardiotoxic effects observed with combination therapies utilizing receptor tyrosine kinase
inhibitors and DOX. The largest benefit was seen in cancers that had mutations to proteins
outside of the PI3K pathway and was especially effective in KRAS mutant pancreatic
cancer. The reason for this is still largely unknown but seems to rely on a combination of
factors, at least one of which may be unique to BEZ. KRAS mutant cancers traditionally
are thought to signal through RAF, MEK, and ERK to transmit its oncogenic signaling in a
process that is independent of PI3K. However, it is now know that the RAS proteins,
including KRAS, directly activate PI3K leading to downstream signaling and pancreatic
cancer has been shown to be dependent on PI3K signaling. With that being said, inhibition
of PI3K and its downstream targets itself does not kill KRAS mutant cells and at most
arrests cell proliferation, which is in contrast to PI3K mutant cells which were sensitive to
BEZ treatment. While tumor growth may arrest for a short time, BEZ likely would not be
an effective monotherapy in cancers which do not have PI3K mutations or HER2
overexpression, as evidenced by the clinical trial data. For that reason, the addition of a
cytotoxic agent like DOX is critical for effective treatment of the cancer. With combination
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treatment, BEZ acts to sensitize the cells so that DOX can efficiently kill the cancer cell.
The sensitizing effect of BEZ may also be the result of decreased metabolic efficiency
through loss of glycolytic enzymes which are under the translational control of AKT and
mTOR. Evidence for this can be seen in microscopy pictures of BEZ treated cells which
seem to have a phenotype resembling nutrient starvation. Future studies are needed to
confirm this but unpublished data from this lab demonstrates that glucose deprivation
sensitizes cells to DOX which seems to support the hypothesis.
BEZ is an inhibitor of ABC transporter mediated efflux of DOX. We describe
BEZ’s direct inhibition of ABCB1 which can overcome the multi-drug resistant
phenotype. However, as evidenced by the increase in DOX accumulation in cells that do
not express a high amount of ABCB1 (MiaPaCa2 and MDA-MB-231), it is highly likely
that BEZ also inhibits other efflux transporters. Studies using overexpression of these other
transporters will be needed to further expand on this interesting observation. Clinically
there are tremendous implications for drugs that can increase tumor drug delivery,
especially considering pure efflux inhibitors have been met with toxicity due to the loss of
endogenous functions of the transporters. BEZ is essentially a dual-role inhibitor, its
primary function being a PI3K/mTOR inhibitor and a novel secondary function of
inhibiting ABC transporter efflux of DOX. Our results suggest that DOX is not a great
substrate for ABCB1 and possibly other transporters. Therefore, BEZ, which we believe to
be a weak inhibitor of ABC efflux proteins, can sufficiently outcompete DOX for the
substrate binding site allowing for nuclear accumulation. However, it would not
outcompete many endogenous substrates needed for biological function of normal cells
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thereby reducing ABC transporter related toxicities. Furthermore, the increased
accumulation of drugs when co-treated with BEZ may be specific to DOX and its related
derivatives as evidenced by the reduction in efficacy when combined with Gem in
pancreatic cancer cells. Moreover, BEZ mediates an increase in expression of efflux
transporters that efficiently transport Gem so the type of drug could have a major impact
on drug efficacy in the clinic.
Another significant finding of this study is that BEZ does not augment the
cardiotoxic effects of DOX. Cardiotoxicity can be severe with DOX if cumulative doses
get too high and clinical trials in combination with trastuzumab had to be discontinued
because it potentiated those effects. Therefore, the finding that BEZ can reduce the
cardiotoxic effects is extremely important. Damage to the heart is generally ascribed to
DOX-induced production of ROS leading to oxidative damage and cell death but may at
least partially be dependent on isoform specific topo II inhibition. Our studies in cancer
cells indicate that DOX induces ABCB8 expression which could have a protective effect
by reducing intramitochondrial iron levels. However, in these cells at least, BEZ had no
effect on expression of this transporter. In the heart, it has been shown that ABCB8
expression is decreased after DOX exposure which may mediate the increase in ROS
production and leading to cell death. It would be interesting to see if BEZ had any effects
on expression of ABCB8 in the heart which could explain the observed protective effects.
Also, expression levels of other transporters known to confer resistance to DOX may be
modulated by BEZ to induce protection. Of course inter-species differences can’t be ruled
out as the effects of BEZ on ABC transporter expression could be drastically different in
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humans as that observed in mice. It would be extremely informative to obtain patient
samples from clinical trials using BEZ to assess the change in expression of ABC
transporters to corroborate our pre-clinical studies.
In summary, we propose that combining BEZ with DOX would provide a
beneficial therapeutic option for patients with pancreatic and other cancers. It is our hope
that such a strategy would be significantly better than currently used regimens.
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